Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


Articles published in J Thorac Oncol

Retrieve available abstracts of 722 articles:
HTML format



Single Articles


    February 2024
  1. FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al
    The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming 9th edition of the TNM Classification of Lung Cancer.
    J Thorac Oncol. 2024 Feb 4:S1556-0864(24)00060.
    PubMed     Abstract available


  2. ZHOU RX, Liao HJ, Hu JJ, Xiong H, et al
    Global burden of lung cancer attributable to household fine particulate matter pollution in 204 countries and territories, 1990-2019.
    J Thorac Oncol. 2024 Feb 2:S1556-0864(24)00034.
    PubMed     Abstract available


  3. TORASAWA M, Horinouchi H
    A Response to the Letter to the Editor: "A Paradigm Shift in First-Line Treatment Can Have Many Implications for Second-Line Treatment".
    J Thorac Oncol. 2024;19:351-352.
    PubMed    


  4. NISHIMURA T
    A Paradigm Shift in First-Line Treatment Can Have Many Implications For Second-Line Treatment.
    J Thorac Oncol. 2024;19:350.
    PubMed    


  5. HORITA N, Takase-Minegishi K
    Information Bias Might Exaggerate Lung Cancer Risk of Patients With Rheumatoid Arthritis.
    J Thorac Oncol. 2024;19:348.
    PubMed    


  6. CHANG HC, Gau SY
    Real-World Evidence of the Association Between Rheumatoid Arthritis and Lung Cancer.
    J Thorac Oncol. 2024;19:346.
    PubMed    


  7. YUAN C, Huang R, Wang Y
    An Error in Modeling and the Selection of Independent Radiomics Variables Need Caution.
    J Thorac Oncol. 2024;19:344-345.
    PubMed    


  8. BERMAS BL, Gerber DE
    The Joint Problem of Rheumatoid Arthritis and Lung Cancer.
    J Thorac Oncol. 2024;19:196-198.
    PubMed    


  9. VOKES EE, Mornex F, Sezer A, Cheng Y, et al
    Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
    J Thorac Oncol. 2024;19:285-296.
    PubMed     Abstract available


  10. REMON J, Saw SPL, Cortiula F, Singh PK, et al
    Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.
    J Thorac Oncol. 2024;19:199-215.
    PubMed     Abstract available


  11. DACIC S, Cao X, Bota-Rabassedas N, Sanchez-Espiridion B, et al
    Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment.
    J Thorac Oncol. 2024;19:273-284.
    PubMed     Abstract available


  12. OWONIKOKO TK
    SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?
    J Thorac Oncol. 2024;19:193-195.
    PubMed    


  13. LE X
    Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC.
    J Thorac Oncol. 2024;19:190-192.
    PubMed    


  14. LEE JH
    Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?
    J Thorac Oncol. 2024;19:187-189.
    PubMed    


  15. SHIRAISHI Y, Tokito T, Toyozawa R, Inagaki C, et al
    Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
    J Thorac Oncol. 2024;19:337-343.
    PubMed     Abstract available


    January 2024
  16. SHI Y, Hu X, Li X, Gong C, et al
    Ficonalkib (SY-3505) in Advanced ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Open-Label, Single-Arm, Phase I/? Study.
    J Thorac Oncol. 2024 Jan 29:S1556-0864(24)00035.
    PubMed     Abstract available


  17. SHI Y, Chen J, Yang R, Wu H, et al
    Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase III study (INSPIRE).
    J Thorac Oncol. 2024 Jan 25:S1556-0864(24)00033.
    PubMed     Abstract available


  18. NASSAR AH, Kim SY, Aredo JV, Feng J, et al
    Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
    J Thorac Oncol. 2024 Jan 24:S1556-0864(24)00032.
    PubMed     Abstract available


  19. SIMONS E, Camidge DR
    Lung cancer oncogene-directed therapy, fertility and pregnancy.
    J Thorac Oncol. 2024 Jan 5:S1556-0864(24)00023.
    PubMed     Abstract available


  20. YU S, Feng J
    Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial".
    J Thorac Oncol. 2024;19:173-174.
    PubMed    


  21. TANIZAKI J, Hayashi H
    Unraveling Pseudo Kidney Injury: The Significance of Understanding Our "MATE" in Molecular-Targeted Therapies.
    J Thorac Oncol. 2024;19:15-17.
    PubMed    


  22. BATAH H, Majeed Z, Moudgil R
    Tale of Two Cs: Inter-Relationship Between Cardiovascular and Lung Cancer.
    J Thorac Oncol. 2024;19:13-14.
    PubMed    


  23. SINGHAL S, Gandara D, Riess JW
    Mapping EGFR Exon 20 Resistance Mutations: An Intricate Landscape.
    J Thorac Oncol. 2024;19:10-12.
    PubMed    


  24. FANG W, Girard N, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2024;19:52-70.
    PubMed     Abstract available


  25. CHEN MF, Harada G, Liu D, DeMatteo R, et al
    Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.
    J Thorac Oncol. 2024;19:153-159.
    PubMed     Abstract available


  26. UDAGAWA H, Nilsson MB, Robichaux JP, He J, et al
    HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
    J Thorac Oncol. 2024;19:106-118.
    PubMed     Abstract available


  27. HAMADA A, Suda K, Nishino M, Obata K, et al
    Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
    J Thorac Oncol. 2024;19:71-79.
    PubMed     Abstract available


  28. LAM S, Wynes MW, Connolly C, Ashizawa K, et al
    The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative.
    J Thorac Oncol. 2024;19:94-105.
    PubMed     Abstract available


  29. TAGLIAMENTO M, Di Maio M, Remon J, Bironzo P, et al
    Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
    J Thorac Oncol. 2024;19:166-172.
    PubMed     Abstract available


    December 2023
  30. YANG JC, Han B, De La Mora Jimenez E, Lee JS, et al
    Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non?Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/=1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
    J Thorac Oncol. 2023 Dec 28:S1556-0864(23)02432.
    PubMed     Abstract available


  31. ODINTSOV I, Makarem M, Nishino M, Bachert SE, et al
    Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2023 Dec 26:S1556-0864(23)02428.
    PubMed     Abstract available


  32. BISCHOFF P, Reck M, Overbeck T, Christopoulos P, et al
    Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (>/=50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM).
    J Thorac Oncol. 2023 Dec 12:S1556-0864(23)02423.
    PubMed     Abstract available


  33. VAN SCHIL PE, Asamura H, Nishimura KK, Rami-Porta R, et al
    The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02411.
    PubMed     Abstract available


  34. LI W, Fei K, Guo L, Wang Y, et al
    CD74/SLC34A2-ROS1 fusion variants involving the transmembrane region predict poor response to crizotinib in non-small cell lung cancer independent of TP53 mutations.
    J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02414.
    PubMed     Abstract available


  35. DACIC S, Travis WD, Giltnane JM, Kos F, et al
    Artificial intelligence-powered assessment of pathologic response to neoadjuvant atezolizumab in patients with non-small cell lung cancer: results from the LCMC3 study.
    J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02415.
    PubMed     Abstract available


  36. XHEMALAJ D, Gradica F, Skenduli I, Tula J, et al
    Lung Cancer in Albania.
    J Thorac Oncol. 2023;18:1632-1637.
    PubMed    


  37. FERREIRA M, Redman MW, Reckamp KL
    Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.
    J Thorac Oncol. 2023;18:1629-1631.
    PubMed    


  38. LI Z, Lu S
    Third-Generation EGFR Tyrosine Kinase Inhibitor for Central Nervous System Metastases EGFR-Mutant NSCLC: Current Evidence and Future Perspectives.
    J Thorac Oncol. 2023;18:1625-1628.
    PubMed    


  39. MAKAREM M, Rotow JK
    Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response.
    J Thorac Oncol. 2023;18:1615-1617.
    PubMed    


  40. RUFFINI E, Huang J, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023;18:1655-1671.
    PubMed     Abstract available


  41. MAROM EM, Fang W, Ruffini E, Detterbeck F, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic
    J Thorac Oncol. 2023;18:1672-1688.
    PubMed     Abstract available


  42. OKUMURA M, Marino M, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023;18:1638-1654.
    PubMed     Abstract available


  43. ANG YLE, Soo RA
    Has the Ship Sailed on Second-Generation ALK Tyrosine Kinase Inhibitors in the Post-Crizotinib Setting?
    J Thorac Oncol. 2023;18:1621-1624.
    PubMed    


  44. MEDINA CG, Xu Y, Ripley RT
    International Prognostic Modeling: A Platform for Collaborative Approach for Patients With Mesothelioma.
    J Thorac Oncol. 2023;18:1618-1620.
    PubMed    


  45. SOO RA, Cho BC, Kim JH, Ahn MJ, et al
    Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
    J Thorac Oncol. 2023;18:1756-1766.
    PubMed     Abstract available


  46. WOLF AS, Rosenthal A, Giroux DJ, Nowak AK, et al
    The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.
    J Thorac Oncol. 2023;18:1689-1702.
    PubMed     Abstract available


    November 2023
  47. WANG K, Du R, Myall NJ, Lewis WE, et al
    BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02376.
    PubMed     Abstract available


  48. O'LEARY CL, Pierce N, Patel SP, Naidoo J, et al
    Immune-Related Toxicity in Non-small cell Lung Cancer: Current State-of-The-Art and Emerging Clinical Challenges.
    J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02374.
    PubMed     Abstract available


  49. LIAO W, Fehnel C, Goss J, Shepherd CJ, et al
    Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening in a Mississippi Delta Cohort.
    J Thorac Oncol. 2023 Nov 18:S1556-0864(23)02371.
    PubMed     Abstract available


  50. LU C, Wei XW, Wang Z, Zhou Z, et al
    Allelic context of EGFR C797X mutant lung cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes.
    J Thorac Oncol. 2023 Nov 17:S1556-0864(23)02372.
    PubMed     Abstract available


  51. HENSCHKE C, Huber R, Jiang L, Yang D, et al
    Perspective on Management of LDCT Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening From the IASLC Early Detection & Screening Committee.
    J Thorac Oncol. 2023 Nov 16:S1556-0864(23)02369.
    PubMed     Abstract available


  52. GULATI S, Ivic-Pavlicic T, Joasil J, Flores R, et al
    Outcomes in Incidentally Versus Screening Detected Stage I Lung Cancer Surgery Patients.
    J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02364.
    PubMed     Abstract available


  53. CARTMEL B, Fucito LM, Bold KW, Neveu S, et al
    No Additional Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening: Brief Report of a Randomized Trial.
    J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02368.
    PubMed     Abstract available


  54. YANG JJ, Wen W, Zahed H, Zheng W, et al
    Lung Cancer Risk Prediction Models for Asian Ever-Smokers.
    J Thorac Oncol. 2023 Nov 7:S1556-0864(23)02352.
    PubMed     Abstract available


  55. KUBO N, Suefuji H, Nakajima M, Tokumaru S, et al
    Five-year survival outcomes after carbon-ion radiotherapy for operable stage I non-small cell lung cancer: a Japanese national registry study (J-CROS-LUNG).
    J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02346.
    PubMed     Abstract available


  56. HARATAKE N, Ozawa H, Morimoto Y, Yamashita N, et al
    MUC1-C IS A COMMON DRIVER OF ACQUIRED OSIMERTINIB RESISTANCE IN NON-SMALL CELL LUNG CANCER.
    J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02348.
    PubMed     Abstract available


  57. HONG TH, Hwang S, Cho J, Choi YL, et al
    Clinical Significance of the Proposed Pathologic Criteria for Invasion by the International Association for the Study of Lung Cancer in Resected Nonmucinous Lung Adenocarcinoma.
    J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02311.
    PubMed     Abstract available


  58. QIU Z, Huang H, Zhang Y, Chen D, et al
    Comment on "Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report".
    J Thorac Oncol. 2023;18:e138-e139.
    PubMed    


  59. LI A, Yang Y, Zhang L, Hong S, et al
    STK11/LKB1 and Immune Phenotypes Co-Determine Immunotherapy Outcomes.
    J Thorac Oncol. 2023;18:e135-e138.
    PubMed    


  60. AMORI G, Sugawara E, Inamura K
    Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in NSCLC: STK11 Deficiency and Beyond.
    J Thorac Oncol. 2023;18:e134-e135.
    PubMed    


  61. CHEN WM, Yu YH, Chen M, Shia BC, et al
    Correspondence: The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
    J Thorac Oncol. 2023;18:e132-e134.
    PubMed    


  62. ZHANG Y, Dai K, He D, Chen Z, et al
    The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
    J Thorac Oncol. 2023;18:e130-e131.
    PubMed    


  63. NIU Y, Yao F, Yang H
    "Keaping" an Eye on the NRF2 Signature Score: Expanding Its Applicability in Lung Cancer.
    J Thorac Oncol. 2023;18:e126-e128.
    PubMed    


  64. MARTI JLG, Wells JZ, Wells A
    Statins as a Secondary Preventive Agent for Metastatic Cancer.
    J Thorac Oncol. 2023;18:e125-e126.
    PubMed    


  65. OKONTA KE, Baiyewu LA, Jimoh MA
    Lung Cancer in Nigeria.
    J Thorac Oncol. 2023;18:1446-1457.
    PubMed    


  66. DAGOGO-JACK I
    We Don't Talk (Enough) About BRAF.
    J Thorac Oncol. 2023;18:1443-1445.
    PubMed    


  67. LEE JB, Ou SI
    Plasma Genotyping From the CROWN, ALTA-1L, and ALEX Trials: Can We Speak With One Voice on What to Test, How to Test, When to Test, and for What Purpose?
    J Thorac Oncol. 2023;18:1434-1442.
    PubMed    


  68. HIJAZO-PECHERO S, Munoz-Pinedo C, Nadal E
    A Transcriptomic Approach Outperforms Mutational Analysis to Identify KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC.
    J Thorac Oncol. 2023;18:1431-1433.
    PubMed    


  69. SOZZI G, Pastorino U
    Small RNAs Do It Better.
    J Thorac Oncol. 2023;18:1428-1430.
    PubMed    


  70. YANKELEVITZ DF, Yip R, Henschke CI
    Considerations for Incorporating Family History Into Low-dose Computed Tomography Screening Recommendations.
    J Thorac Oncol. 2023;18:1426-1427.
    PubMed    


  71. SAKAI T, Matsumoto S, Ueda Y, Shibata Y, et al
    Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
    J Thorac Oncol. 2023;18:1538-1549.
    PubMed     Abstract available


  72. AHN MJ, Bondarenko I, Kalinka E, Cho BC, et al
    Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
    J Thorac Oncol. 2023;18:1594-1606.
    PubMed     Abstract available


    October 2023
  73. WANG L, Luo Y, Ren S, Zhang Z, et al
    A phase Ib study of ivonescimab, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced or metastatic immunotherapy naive non-small-cell lung cancer.
    J Thorac Oncol. 2023 Oct 23:S1556-0864(23)02312.
    PubMed     Abstract available


  74. HUANG J, Osarogiagbon RU, Giroux DJ, Nishimura KK, et al
    The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 9th Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2023 Oct 20:S1556-0864(23)02310.
    PubMed     Abstract available


  75. CHO MH, Cho JH, Eun Y, Han K, et al
    Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study.
    J Thorac Oncol. 2023 Oct 12:S1556-0864(23)02293.
    PubMed     Abstract available


  76. STOCKHAMMER P, Grant M, Wurtz A, Foggetti G, et al
    Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer.
    J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02264.
    PubMed     Abstract available


  77. HENSCHKE CI, Yip R, Sun Q, Li P, et al
    Prospective Cohort Study to Compare Long-term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a-b;
    J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02265.
    PubMed     Abstract available


  78. ROTOW JK, Lee JK, Madison RW, Oxnard GR, et al
    Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms, and clinical landscape of non-small cell lung cancer (NSCLC) post-osimertinib.
    J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02263.
    PubMed     Abstract available


  79. TRIPHURIDET N, Gao Y, Ou SI
    Reply to Jayaraj et al. "Clinical Validity and Conceptual Interpretation of the Meta-Analysis on the Efficacy of LDCT Lung Cancer Screening in Never-Smokers".
    J Thorac Oncol. 2023;18:e122-e123.
    PubMed    


  80. JAYARAJ R, Shetty S, Ilankumaran S, Merchant Y, et al
    Clinical Validity and Conceptual Interpretation of Low-Dose Computed Tomography Screening in Asian Female Never-Smokers Are as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers.
    J Thorac Oncol. 2023;18:e118-e122.
    PubMed    


  81. CHOUR A, Duruisseaux M
    Response to Commentary on "Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-PD(L)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer".
    J Thorac Oncol. 2023;18:e114-e115.
    PubMed    


  82. DETTERBECK FC, Asamura H, Rami-Porta R, Rusch VW, et al
    The Only Constant Is Change: Introducing the International Association for the Study of Lung Cancer Proposals for the Ninth Edition of TNM Stage Classification of Thoracic Tumors.
    J Thorac Oncol. 2023;18:1258-1260.
    PubMed    


  83. INAMURA K
    Exploiting Tumor Immune Microenvironment to Predict Response to Immunotherapy Plus Chemotherapy in NSCLC.
    J Thorac Oncol. 2023;18:e109-e110.
    PubMed    


  84. ADJEI AA
    The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in 2024.
    J Thorac Oncol. 2023;18:1257.
    PubMed    


  85. HOE HJ, Balasubramanian A, John T
    LASERing FLAURAL Arrangements in Asian EGFR Subsets.
    J Thorac Oncol. 2023;18:1261-1264.
    PubMed    


  86. REUNGWETWATTANA T, Cho BC, Lee KH, Pang YK, et al
    Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naive Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
    J Thorac Oncol. 2023;18:1351-1361.
    PubMed     Abstract available


  87. PEARSALL SM, Williamson SC, Humphrey S, Hughes E, et al
    Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry.
    J Thorac Oncol. 2023;18:1362-1385.
    PubMed     Abstract available


  88. GELSOMINO F, Vitale G, Raschi E, Ardizzoni A, et al
    Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue.
    J Thorac Oncol. 2023;18:e112-e113.
    PubMed    


  89. CHEN WM, Yu YH, Chen M, Shia BC, et al
    Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma.
    J Thorac Oncol. 2023;18:e107-e109.
    PubMed    


  90. LIN TA, Chen SY, Chang R, Sun CK, et al
    Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study.
    J Thorac Oncol. 2023;18:e105-e106.
    PubMed    


  91. WRIGHT K, Digby GC, Gyawali B, Jad R, et al
    Malignant Superior Vena Cava Syndrome: A Scoping Review.
    J Thorac Oncol. 2023;18:1268-1276.
    PubMed     Abstract available


    September 2023
  92. DUAN J, Wu L, Yang K, Zhao J, et al
    Safety, tolerability, pharmacokinetics, and preliminary efficacy of YK-029A in treatment-naive patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations: A phase I trial.
    J Thorac Oncol. 2023 Sep 28:S1556-0864(23)02259.
    PubMed     Abstract available


  93. RECK M, Barlesi F, Chih-Hsin Yang J, Westeel V, et al
    Avelumab vs platinum-based doublet chemotherapy as first-line treatment for patients with high-expression PD-L1+ metastatic non-small cell lung cancer: primary analysis from the phase 3 JAVELIN Lung 100 trial.
    J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02250.
    PubMed     Abstract available


  94. JIANG C, Zhang Y, Fu F, Deng P, et al
    A Shift in Paradigm: Selective Lymph Node Dissection for Minimizing Oversurgery in Early-Stage Lung Cancer.
    J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02245.
    PubMed     Abstract available


  95. TORASAWA M, Horinouchi H, Nomura S, Igawa S, et al
    Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.
    J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02256.
    PubMed     Abstract available


  96. WANG X, Bai H, Zhang J, Wang Z, et al
    Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer.
    J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01079.
    PubMed     Abstract available


  97. FIGUEROA PU, Marques E, Cilento VJ, Giroux DJ, et al
    Completeness of Resection and Long-term Survival of Patients Undergoing Resection for Pathological T3 Non-small-cell Lung Cancer: An International Association for the Study of Lung Cancer Analysis.
    J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01078.
    PubMed     Abstract available


  98. ZHANG S, Liu L, Shi S, He H, et al
    Bidirectional association between cardiovascular disease and lung cancer in a prospective cohort study.
    J Thorac Oncol. 2023 Sep 11:S1556-0864(23)00806.
    PubMed     Abstract available


  99. DINGEMANS AC, Mathijssen RHJ, van Rossum EFC
    Approach to Alectinib-Induced Body Weight Gain in Patients With ALK+ Non-Small Lung Cancer.
    J Thorac Oncol. 2023;18:e99-e100.
    PubMed    


  100. LEE ATM, Ou SI, Lisberg A
    Letter to Editor. Re "de Leeuw SP, et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK Positive Lung Cancer," Semaglutide a Potential Treatment for Serious Weight Gain From ALK Tyrosine Kinase Inhibitors?
    J Thorac Oncol. 2023;18:e97-e99.
    PubMed    


  101. GARCIA-PARDO M, Liu G
    Re: Response to Letter to the Editor "Respiratory and Cardiometabolic Comorbidities and Stage I-III Non-Small Cell Lung Cancer (NSCLC) Survival: A Pooled Analysis From the International Lung Cancer Consortium".
    J Thorac Oncol. 2023;18:e96-e97.
    PubMed    


  102. ZHANG Y, Zhang J
    Comment on "Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium".
    J Thorac Oncol. 2023;18:e95-e96.
    PubMed    


  103. FUJITA T, Amano H, Nakamura M, Hirano S, et al
    Remarkable Response to Immune Checkpoint Inhibitor Monotherapy in an EGFR-Mutant Pulmonary Adenocarcinoma Patient With 0% Expression of PD-L1.
    J Thorac Oncol. 2023;18:e93-e94.
    PubMed    


  104. PONVILAWAN B, Sharma P, Mahadevia H, Subramanian J, et al
    Outcomes of Immunotherapy Versus Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-Analysis of Randomized Clinical Trials.
    J Thorac Oncol. 2023;18:e90-e93.
    PubMed    


  105. HONG TH, Bang YH, Joe C, Choi YL, et al
    Comment on "Leveraging NGS Data to Refine Immunotherapy Response Prediction in NSCLC: PD-L1 Copy Number, Tumor Mutation Burden, and Beyond".
    J Thorac Oncol. 2023;18:e88-e90.
    PubMed    


  106. INAMURA K
    Leveraging Next-Generation Sequencing Data to Refine Immunotherapy Response Prediction in NSCLC: Programmed Death-Ligand 1 Copy Number, Tumor Mutation Burden, and Beyond.
    J Thorac Oncol. 2023;18:e87-e88.
    PubMed    


  107. PAZ-ARES LG, Carbone DP
    Response to the Letter to the Editor Titled "First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA".
    J Thorac Oncol. 2023;18:e102-e103.
    PubMed    


  108. ZHAO B, Ma W
    First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA.
    J Thorac Oncol. 2023;18:e101-e102.
    PubMed    


  109. ASMARA OD, Tenda ED, Singh G, Pitoyo CW, et al
    Lung Cancer in Indonesia.
    J Thorac Oncol. 2023;18:1134-1145.
    PubMed    


  110. MOGHANAKI D, Lisberg A, Oh S, Lee JM, et al
    Unresectable Stage III NSCLC Should Not be Treated With Neoadjuvant Therapy and Re-Evaluated for Resection.
    J Thorac Oncol. 2023;18:1129-1133.
    PubMed    


  111. DICKHOFF C, Heineman DJ, Bahce I, Senan S, et al
    Unresectable Stage III NSCLC Can Be Reevaluated for Resectability After Initial Treatment.
    J Thorac Oncol. 2023;18:1124-1128.
    PubMed    


  112. DENIZE T, Mino-Kenudson M
    "Normal" Is Not Normal: The Role of the Immune Microenvironment of Adjacent Non-Neoplastic Tissue in Dictating the Biology of Early-Stage NSCLC.
    J Thorac Oncol. 2023;18:1121-1123.
    PubMed    


  113. FACCHINETTI F, Janne PA, Tiseo M
    Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era.
    J Thorac Oncol. 2023;18:1118-1120.
    PubMed    


  114. SCHROEDER BA, Thomas A
    SCLC Subtypes and Biomarkers of the Transformative Immunotherapy Responses.
    J Thorac Oncol. 2023;18:1114-1117.
    PubMed    


  115. CORNO C, Beretta GL, Perego P
    Concomitant Targeting of MDM2 and MEK: A New Translatable Combinatorial Strategy?
    J Thorac Oncol. 2023;18:1111-1113.
    PubMed    


  116. OPITZ I, Bille A, Dafni U, Nackaerts K, et al
    European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
    J Thorac Oncol. 2023;18:1233-1247.
    PubMed     Abstract available


  117. FARINEA G, Crespi V, Listi A, Righi L, et al
    The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality.
    J Thorac Oncol. 2023;18:1146-1164.
    PubMed     Abstract available


  118. ELKRIEF A, Odintsov I, Markov V, Caeser R, et al
    Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
    J Thorac Oncol. 2023;18:1165-1183.
    PubMed     Abstract available


    August 2023
  119. CHO BC, Lee JS, Wu YL, Cicin I, et al
    Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1-high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial.
    J Thorac Oncol. 2023 Aug 17:S1556-0864(23)00738.
    PubMed     Abstract available


  120. IMBODY D, Arce K, Solanki HS, Haura EB, et al
    Targeting SHP2 Signaling in Lung Cancer.
    J Thorac Oncol. 2023 Aug 11:S1556-0864(23)00729.
    PubMed    


  121. LI Y, Juergens RA, Finley C, Swaminath A, et al
    Moving Through Inertia - The Promise of Current and Future Treatment Options in the Management of Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2023 Aug 11:S1556-0864(23)00731.
    PubMed     Abstract available


  122. CHIH-HSIN YANG J, Liu G, Lu S, He J, et al
    Brigatinib Versus Alectinib in ALK-positive Non-small Cell Lung Cancer After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.
    J Thorac Oncol. 2023 Aug 11:S1556-0864(23)00730.
    PubMed     Abstract available


  123. LARA-MEJIA L, Cardona AF, Mas L, Martin C, et al
    Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged non-small cell lung cancer.
    J Thorac Oncol. 2023 Aug 10:S1556-0864(23)00727.
    PubMed     Abstract available



  124. In the published article titled "New Fissure-attached Nodules in Lung Cancer Screening: A Brief Report from The NELSON Study", J Thorac Oncol 2019 Jan;15(1):125-129.
    J Thorac Oncol. 2023 Aug 9:S1556-0864(23)00675.
    PubMed    


  125. XIE H, Dai C, Gu C, Zhao S, et al
    Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification to Upgrade Extracapsular Extension of Tumor in Nodes From R0 to Incomplete Resection.
    J Thorac Oncol. 2023 Aug 9:S1556-0864(23)00723.
    PubMed     Abstract available


  126. DACIC S, Travis W, Redman M, Saqi A, et al
    International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
    J Thorac Oncol. 2023 Aug 3:S1556-0864(23)00685.
    PubMed     Abstract available


  127. BEARZ A, Martini JF, Jassem J, Kim SW, et al
    Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4::ALK variant type and ALK with or without TP53 mutations.
    J Thorac Oncol. 2023 Aug 2:S1556-0864(23)00691.
    PubMed     Abstract available


  128. KUS T, Aktas G
    In the Presence of KRAS Comutations With STK11 or KEAP1 Monoimmunotherapy Does Not Work, but Is Not Chemoimmunotherapy Also an Overtreatment?
    J Thorac Oncol. 2023;18:e83-e84.
    PubMed    


  129. CONTRUCCI RR, Ter Heine R, Hendriks LEL, de Rouw N, et al
    Folinic Acid to Prevent Pemetrexed-Associated Neutropenia After Intrathecal Administration: A Quick Win.
    J Thorac Oncol. 2023;18:e81-e82.
    PubMed    


  130. AKINBOBOLA O, Ray MA, Smeltzer MP, Osarogiagbon RU, et al
    In Response: Taichiro Goto "Kit Use May Not Be Key To Improved Prognosis"; Response to "Akinbobola O, Ray MA, Fehnel C, et al. Institution-Level Evolution of Lung Cancer Resection Quality With Implementation of a Lymph Node Specimen Collection Kit".
    J Thorac Oncol. 2023;18:e80-e81.
    PubMed    


  131. GOTO T
    Kit Use May Not Be Key to Improved Prognosis.
    J Thorac Oncol. 2023;18:e79-e80.
    PubMed    


  132. VIDETIC GMM
    Local Treatments of Oligometastatic and Oligoprogressive NSCLC Should Become the Standard of Care.
    J Thorac Oncol. 2023;18:986-989.
    PubMed    


  133. MACBETH F, Treasure T
    Local Treatments of Oligometastatic and Oligoprogressive NSCLC Should Not Become the Standard of Care.
    J Thorac Oncol. 2023;18:981-985.
    PubMed    


  134. ISLAM MR, Siddiqua SM, Islam R, Hossain A, et al
    Lung Cancer in Bangladesh.
    J Thorac Oncol. 2023;18:972-980.
    PubMed    


  135. TAORMINA JM, Camidge DR
    Editorial Related to Leeuw et al.: The Evolution of Expectations: How Our Views On "Acceptable" Toxicities Are Changing With Prolonged Lung Cancer Treatments.
    J Thorac Oncol. 2023;18:967-969.
    PubMed    


  136. BORM FJ, Smit EF
    Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?
    J Thorac Oncol. 2023;18:964-966.
    PubMed    


  137. NORRIS RP, Dew R, Greystoke A, Todd A, et al
    Socioeconomic Inequalities in Novel NSCLC Treatments During the Era of Tumor Biomarker-Guided Therapy: A Population-Based Cohort Study in a Publicly Funded Health Care System.
    J Thorac Oncol. 2023;18:990-1002.
    PubMed     Abstract available


  138. PROTO C, Manglaviti S, Lo Russo G, Musca M, et al
    STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.
    J Thorac Oncol. 2023;18:1070-1081.
    PubMed     Abstract available


  139. CHEN WM, Yu YH, Chen M, Shia BC, et al
    Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study.
    J Thorac Oncol. 2023;18:1082-1093.
    PubMed     Abstract available


  140. LIN SH
    Statin Use and Chemoradiation in Esophageal Squamous Cell Carcinomas: Ready for Prime Time?
    J Thorac Oncol. 2023;18:970-971.
    PubMed    


    July 2023
  141. LI A, Wang Y, Yu Z, Tan Z, et al
    STK11/LKB1 Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/IFN-I/CD8(+) T cell Dysfunction in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2023 Jul 24:S1556-0864(23)00688.
    PubMed     Abstract available


  142. RIMNER A, Ruffini E, Cilento V, Goren E, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: An Overview of the Central Database Informing Revision of the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2023 Jul 24:S1556-0864(23)00672.
    PubMed     Abstract available


  143. LAM S, Bai C, Baldwin D, Chen Y, et al
    Current and Future Perspectives on CT Screening for Lung Cancer: A Road Map for 2023-2027 from the IASLC.
    J Thorac Oncol. 2023 Jul 22:S1556-0864(23)00687.
    PubMed     Abstract available


  144. AROLT C, Dugan M, Wild R, Richartz V, et al
    KEAP1/NFE2L2 pathway signature outperforms KEAP1/NFE2L2 mutation status and reveals alternative pathway-activating mutations in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2023 Jul 18:S1556-0864(23)00684.
    PubMed     Abstract available


  145. LEE JM, McNamee CJ, Toloza E, Negrao MV, et al
    Neoadjuvant Targeted Therapy in Resectable Non-Small Cell Lung Cancer: Current and Future Perspectives.
    J Thorac Oncol. 2023 Jul 12:S1556-0864(23)00671.
    PubMed     Abstract available


  146. SIKOSEK T, Horos R, Trudzinski F, Jehn J, et al
    Early Detection of Lung Cancer using small RNAs.
    J Thorac Oncol. 2023 Jul 10:S1556-0864(23)00670.
    PubMed     Abstract available


  147. RIEDEL R, Fassunke J, Scheel AH, Scheffler M, et al
    Brief Report: MET fusions in Non-small cell lung cancer: Clinicopathologic features and response to MET inhibition.
    J Thorac Oncol. 2023 Jul 8:S1556-0864(23)00666.
    PubMed     Abstract available


  148. EVANS WK, Tammemagi MC, Walker MJ, Cameron E, et al
    Integrating smoking cessation into LDCT lung cancer screening: Results of the Ontario, Canada Pilot.
    J Thorac Oncol. 2023 Jul 6:S1556-0864(23)00669.
    PubMed     Abstract available


  149. WANG CL, Hsu KH, Chang YH, Ho CC, et al
    Low-dose CT screening in relatives with a family history of lung cancer.
    J Thorac Oncol. 2023 Jul 4:S1556-0864(23)00639.
    PubMed     Abstract available


  150. KEOGH RJ, Barr MP, Keogh A, McMahon D, et al
    Lung Cancer in the Republic of Ireland.
    J Thorac Oncol. 2023;18:851-857.
    PubMed    


  151. DOWLATI A, Towe CW, Linden PA
    Who Are You "KITTING"? The Use of Kits to Collect Lymph Nodes During Lung Cancer Surgery.
    J Thorac Oncol. 2023;18:838-840.
    PubMed    


  152. CHOE JK, Li Y, Adusumilli PS
    Response to Letter to the Editor: "Which Percentage of Micropapillary and Solid Histological Patterns in Lymph Node Metastases Is Significantly Associated With Poor Outcomes?".
    J Thorac Oncol. 2023;18:e76-e77.
    PubMed    


  153. NIU Y, He Y, Li Z
    Which Percentage of Micropapillary and Solid Histologic Patterns in Lymph Node Metastases Is Significantly Associated With Poor Outcomes?
    J Thorac Oncol. 2023;18:e75-e76.
    PubMed    


  154. ZHAO B, Qi H, Wu J, Ma W, et al
    Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
    J Thorac Oncol. 2023;18:e72-e73.
    PubMed    


  155. KUNIMASA K, Wada M, Nishino K
    Severe Psychosis Associated With Lorlatinib.
    J Thorac Oncol. 2023;18:e71-e72.
    PubMed    


  156. NADRES B, Momcilovic M, Shackelford DB, Lisberg A, et al
    An Unexpected Partnership: Histone Deacetylase 6 and Glutaminase Inhibition Provide an Opportunity to Overcome Resistance in KRAS and LKB1 Co-mutant Lung Tumors.
    J Thorac Oncol. 2023;18:847-850.
    PubMed    


  157. NORMAN A, Adjei AA
    Expanding the KRASG12C Inhibitor Class: What Do We Need Next?
    J Thorac Oncol. 2023;18:844-846.
    PubMed    


  158. COOPER WA, John T
    Rethinking Biomarkers for Combination Chemoimmunotherapy.
    J Thorac Oncol. 2023;18:841-843.
    PubMed    


  159. KIM HK
    Selective Mediastinal Lymph Node Dissection: Precision Surgery in the Era of Precision Medicine.
    J Thorac Oncol. 2023;18:834-837.
    PubMed    


  160. MINCHOM A, Popat S
    Sitravatinib and Acquired Immune Checkpoint Inhibitor Resistance: A Gem for the Future?
    J Thorac Oncol. 2023;18:830-833.
    PubMed    


  161. LAU BC, Wu YF, No HJ, Ko RB, et al
    Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Antiangiogenic Agents.
    J Thorac Oncol. 2023;18:922-930.
    PubMed     Abstract available


  162. SUN D, Liu J, Zhou H, Shi M, et al
    Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC.
    J Thorac Oncol. 2023;18:869-881.
    PubMed     Abstract available


    June 2023
  163. GILLESPIE CS, Mustafa MA, Richardson GE, Alam AM, et al
    Genomic alterations and the incidence of brain metastases in advanced and metastatic non-small cell lung cancer: a systematic review and meta-analysis.
    J Thorac Oncol. 2023 Jun 29:S1556-0864(23)00638.
    PubMed     Abstract available


  164. CHI-LEUNG LAM D, Liam CK, Andarini S, Park S, et al
    Lung Cancer Screening in Asia: An Expert Consensus Report.
    J Thorac Oncol. 2023 Jun 28:S1556-0864(23)00635.
    PubMed     Abstract available


  165. PIETROLUONGO E, De Placido P, Tortora M, Martinelli C, et al
    Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic epithelial tumors.
    J Thorac Oncol. 2023 Jun 28:S1556-0864(23)00634.
    PubMed     Abstract available


  166. HARATANI K, Nakamura A, Mamesaya N, Mitsuoka S, et al
    Tumor microenvironment landscape of non-small cell lung cancer reveals resistance mechanisms for PD-L1 blockade following chemoradiotherapy: a multi-center prospective biomarker study (WJOG11518L/SUBMARINE).
    J Thorac Oncol. 2023 Jun 24:S1556-0864(23)00633.
    PubMed     Abstract available


  167. JUNG HA, Ku BM, Kim YJ, Park S, et al
    Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stage I-IIIA EGFR Mutant-Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2023 Jun 10:S1556-0864(23)00607.
    PubMed     Abstract available


  168. SOO RA, Martini JF, van der Wekken AJ, Teraoka S, et al
    Early ctDNA dynamics and efficacy of lorlatinib in patients with treatment-naive, advanced, ALK-positive non-small cell lung cancer.
    J Thorac Oncol. 2023 Jun 7:S1556-0864(23)00580.
    PubMed     Abstract available


  169. BERG CD, Schiller JH, Boffetta P, Cai J, et al
    AIR POLLUTION AND LUNG CANCER A Review by International Association for the Study of Lung Cancer Early Detection and Screening Committee.
    J Thorac Oncol. 2023 Jun 3:S1556-0864(23)00601.
    PubMed     Abstract available


  170. PICCIRILLO MC, Chu Q, Bradbury P, Seymour L, et al
    Response to a Letter Received Entitled: "'Brief Report: Canadian Cancer Trials Group IND.227': Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma".
    J Thorac Oncol. 2023;18:e68-e69.
    PubMed    


  171. GEMELLI M
    "Brief Report: Canadian Cancer Trials Group IND.227": Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2023;18:e67-e68.
    PubMed    


  172. NAKASHIMA K, Tsubata Y, Isobe T
    Successful Pembrolizumab Rechallenge in a Patient With Advanced NSCLC After Pemetrexed-Induced Palm Pustules.
    J Thorac Oncol. 2023;18:e66-e67.
    PubMed    


  173. MA Z, Yang X, Hui Z
    Association of Heart Base Dose With Overall Survival in Patients With NSCLC Undergoing Postoperative Radiotherapy.
    J Thorac Oncol. 2023;18:e62-e64.
    PubMed    


  174. ZHAO B, Wu J, Ma W
    Clinical and Genomic Factors Predicting the Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
    J Thorac Oncol. 2023;18:e59-e60.
    PubMed    


  175. SMELTZER MP, Liao W, Osarogiagbon RU
    In Response: Letter to the Editor: Re "Smeltzer MP, Liao W, Faris NR, et al. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening".
    J Thorac Oncol. 2023;18:e58-e59.
    PubMed    


  176. TRIPHURIDET N, Ou SI
    Reply to "Smeltzer MP, Liao W, Faris NR, et al. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening. J Thorac Oncol. 2023;18(2):158-168".
    J Thorac Oncol. 2023;18:e57-e58.
    PubMed    


  177. CARBONE M, Yang H, Pass HI, Taioli E, et al
    Did the Ban on Asbestos Reduce the Incidence of Mesothelioma?
    J Thorac Oncol. 2023;18:694-697.
    PubMed    


  178. CHIU CH, Yang PC
    Never Say No to Never-Smokers.
    J Thorac Oncol. 2023;18:689-693.
    PubMed    


  179. DELASOS L, Madabhushi A, Patil PD
    Can Radiomics Bridge the Gap Between Immunotherapy and Precision Medicine in Lung Cancer?
    J Thorac Oncol. 2023;18:686-688.
    PubMed    


  180. LIM JH, Lee S, Ryu JS
    Prediction of Treatment Response to Chemoimmunotherapy: Concerted Effort Needed.
    J Thorac Oncol. 2023;18:682-685.
    PubMed    


  181. ACKER F, Althoff FC, Sebastian M
    Systemic Treatment for Brain Metastases in NSCLC: A New Chapter.
    J Thorac Oncol. 2023;18:678-681.
    PubMed    


  182. ROLFO C, Russo A
    Exploiting the Full Potential of Novel Agents Targeting EGFR Exon 20 Insertions in Advanced NSCLC: Next-Generation Sequencing Outperforms Polymerase Chain Reaction-Based Testing.
    J Thorac Oncol. 2023;18:674-677.
    PubMed    


  183. MAKHARADZE T, Gogishvili M, Melkadze T, Baramidze A, et al
    Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
    J Thorac Oncol. 2023;18:755-768.
    PubMed     Abstract available


  184. PICCIRILLO MC, Chu Q, Bradbury P, Tu W, et al
    Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).
    J Thorac Oncol. 2023;18:813-819.
    PubMed     Abstract available


  185. HUANG J, Chan SC, Pang WS, Chow SH, et al
    Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study.
    J Thorac Oncol. 2023;18:792-802.
    PubMed     Abstract available


    May 2023
  186. ALESSI JV, Wang X, Elkrief A, Ricciuti B, et al
    Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in non-small cell lung cancer.
    J Thorac Oncol. 2023 May 27:S1556-0864(23)00578.
    PubMed     Abstract available


  187. JOHN T, Grohe C, Goldman JW, Shepherd FA, et al
    Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients with Resected Stage IB-IIIA EGFR-Mutated Non-Small Cell Lung Cancer: Updated Analysis from the Phase 3 ADAURA Trial.
    J Thorac Oncol. 2023 May 24:S1556-0864(23)00574.
    PubMed     Abstract available


  188. CHOUR A, Denis J, Mascaux C, Zysman M, et al
    Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRAS(G12C)-mutant lung cancer.
    J Thorac Oncol. 2023 May 20:S1556-0864(23)00572.
    PubMed     Abstract available


  189. RUDIN CM, Balli D, Lai WV, Richards AL, et al
    Clinical benefit from immunotherapy in patients with small cell lung cancer is associated with tumor capacity for antigen presentation.
    J Thorac Oncol. 2023 May 18:S1556-0864(23)00554.
    PubMed     Abstract available


  190. CHENG C, Hong W, Li Y, Xiao X, et al
    Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis.
    J Thorac Oncol. 2023 May 5:S1556-0864(23)00527.
    PubMed     Abstract available


  191. RECK M, Ciuleanu TE, Lee JS, Schenker M, et al
    Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic non-small cell lung cancer and baseline brain metastases from CheckMate 227 Part 1.
    J Thorac Oncol. 2023 May 3:S1556-0864(23)00525.
    PubMed     Abstract available


  192. GARON EB, Spira AI, Goldberg SB, Chaft JE, et al
    Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in PD-(L)1-Monotherapy Pretreated, Advanced Non-Small Cell Lung Cancer: Results From a Phase 1b Clinical Trial.
    J Thorac Oncol. 2023 May 3:S1556-0864(23)00524.
    PubMed     Abstract available


  193. CHENG C, Nguyen TT, Tang M, Wang X, et al
    Immune infiltration in tumor and adjacent non-neoplastic regions co-determines patient clinical outcomes in early-stage lung cancer.
    J Thorac Oncol. 2023 May 3:S1556-0864(23)00526.
    PubMed     Abstract available


  194. ZHOU F, Zhou C
    Notch Mutations as a Novel Biomarker for Immunotherapy.
    J Thorac Oncol. 2023;18:e54-e56.
    PubMed    


  195. KUNIMASA K
    Notch Mutations as a Novel Biomarker for Immunotherapy.
    J Thorac Oncol. 2023;18:e53-e54.
    PubMed    


  196. MURCIANO-GOROFF YR, Lin ST, Wilhelm C, Iasonos A, et al
    In Reply to "Selpercatinib Controls Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC".
    J Thorac Oncol. 2023;18:e52-e53.
    PubMed    


  197. ZHAO B, Xing H, Ma W
    Selpercatinib Controls Central Nervous System Disease in Patients With NSCLC With RET Fusion.
    J Thorac Oncol. 2023;18:e51-e52.
    PubMed    


  198. YANG CY, Lin YT, Lin LJ, Yang PC, et al
    Response to Letter to the Editor: "Factors Other Than Low-Dose Computed Tomography Screening Related to Stage Shift and Improved Survival of Lung Cancer".
    J Thorac Oncol. 2023;18:e49-e51.
    PubMed    


  199. INAGAKI Y
    Factors Other Than Low-Dose Computed Tomography Screening Related to Stage Shift and Improved Survival of Lung Cancer.
    J Thorac Oncol. 2023;18:e48-e49.
    PubMed    


  200. OKUBO Y, Yatabe Y
    Reply to the Letter to the Editor From He Y et al.
    J Thorac Oncol. 2023;18:e46-e48.
    PubMed    


  201. HE Y, Zhang J, Li Z
    The Protective and Risk Factors Affecting the Prognosis of Pathologic Stage IA Adenocarcinoma: How to Balance?
    J Thorac Oncol. 2023;18:e45-e46.
    PubMed    


  202. LAU SCM, Ou SI
    Selpercatinib as the Guardian of the Central Nervous System for Patients With RET Fusion-Positive NSCLC?
    J Thorac Oncol. 2023;18:561-563.
    PubMed    


  203. NAKAJIMA J
    Minimally Invasive Thymectomy Could Be Attempted for Locally Advanced Thymic Malignancies: A Real-World Study With Propensity Score-Matched Analysis.
    J Thorac Oncol. 2023;18:559-560.
    PubMed    


  204. ERASMUS JJ, Vlahos I
    Editorial Commentary: Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC.
    J Thorac Oncol. 2023;18:556-558.
    PubMed    


  205. HORINOUCHI H
    Another Pirate in the Red Ocean? CD73-Targeted Therapy in EGFR-Mutated NSCLC.
    J Thorac Oncol. 2023;18:552-555.
    PubMed    


  206. SUN L, Marmarelis M, Aggarwal C
    Re-Evaluating Real-World Evidence in RET Fusion-Positive NSCLC: Are Randomized Clinical Trials Needed?
    J Thorac Oncol. 2023;18:549-551.
    PubMed    


  207. NAIDOO J, Antonia S, Wu YL, Cho BC, et al
    Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
    J Thorac Oncol. 2023;18:657-663.
    PubMed     Abstract available


  208. MCWILLIAM A, Abravan A, Banfill K, Faivre-Finn C, et al
    Demystifying the Results of RTOG 0617: Identification of Dose Sensitive Cardiac Subregions Associated With Overall Survival.
    J Thorac Oncol. 2023;18:599-607.
    PubMed     Abstract available


  209. LI Y, Byun AJ, Choe JK, Lu S, et al
    Micropapillary and Solid Histologic Patterns in N1 and N2 Lymph Node Metastases Are Independent Factors of Poor Prognosis in Patients With Stages II to III Lung Adenocarcinoma.
    J Thorac Oncol. 2023;18:608-619.
    PubMed     Abstract available


  210. ZHOU C, Chen G, Huang Y, Zhou J, et al
    Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.
    J Thorac Oncol. 2023;18:628-639.
    PubMed     Abstract available


  211. GU Z, Hao X, Liu Y, Xu N, et al
    Minimally Invasive Thymectomy Could Be Attempted for Locally Advanced Thymic Malignancies: A Real-World Study With Propensity Score-Matched Analysis.
    J Thorac Oncol. 2023;18:640-649.
    PubMed     Abstract available


    April 2023
  212. PARK CK, Oh HJ, Kim YC, Kim YH, et al
    Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Durvalumab after Chemoradiotherapy: PACIFIC-KR.
    J Thorac Oncol. 2023 Apr 19:S1556-0864(23)00495.
    PubMed     Abstract available


  213. HONG TH, Bang YH, Joe C, Hwang S, et al
    Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2023 Apr 5:S1556-0864(23)00482.
    PubMed     Abstract available


  214. WANG Y, Che G
    Authors' Reply to Letter to the Editor Regarding the Article "Risk and Influencing Factors for Subsequent Primary Lung Cancer After Treatment of Breast Cancer: A Systematic Review and Two Meta-Analyses Based on Four Million Cases".
    J Thorac Oncol. 2023;18:e46-e47.
    PubMed    


  215. WANG H, Yang R, Li W
    Letter to the Editor Regarding the Article "Risk and Influencing Factors for Subsequent Primary Lung Cancer After Treatment of Breast Cancer: A Systematic Review and Two Meta-Analyses Based on Four Million Cases".
    J Thorac Oncol. 2023;18:e44-e45.
    PubMed    


  216. HAN DH, Duan F, Patz EF Jr
    Response to Letter to the Editor About Clinical Significance of Lung-RADS Category 3 Lesions.
    J Thorac Oncol. 2023;18:e41-e42.
    PubMed    


  217. LI Z, He Y, Xiong Z
    Letter to the Editor About Clinical Significance of Lung-RADS Category 3 Lesions.
    J Thorac Oncol. 2023;18:e40-e41.
    PubMed    


  218. GIRARD N, Garassino MC, Solomon B
    Response to Letter to the Editor From Binghao Zhao et al.
    J Thorac Oncol. 2023;18:e40-e41.
    PubMed    


  219. ZHAO B, Li H, Ma W
    Durvalumab After Chemoradiotherapy for Patients With Unresectable Stage III NSCLC: The PACIFIC-R Study.
    J Thorac Oncol. 2023;18:e38-e39.
    PubMed    


  220. NG JKM, Chan CF, Li JJX
    Thymic Carcinoma With Malignant Effusion-a Rare Cytologic and Radiologic Mimicker of Metastatic NSCLC.
    J Thorac Oncol. 2023;18:e35-e37.
    PubMed    


  221. CHEN CH, Hsu CK, Lee CN
    Tepotinib-Induced Palmoplantar Keratoderma-Like Hand-Foot Skin Reaction.
    J Thorac Oncol. 2023;18:e33-e34.
    PubMed    


  222. ZOHRABYAN D, Karapetyan N, Danielyan S, Saghatelyan T, et al
    Lung Cancer in Armenia.
    J Thorac Oncol. 2023;18:402-409.
    PubMed    


  223. EBI H
    Drug-Tolerant Persister Cells After EGFR Tyrosine Kinase Inhibitor Treatment: Their Origin and the Influences From the Tumor Microenvironment.
    J Thorac Oncol. 2023;18:399-401.
    PubMed    


  224. MOREIRA AL, Sabari JK
    Seeing Beyond the Smoke: Reclassifying Lung Cancer by Smoking-Related Mutational Signatures.
    J Thorac Oncol. 2023;18:396-398.
    PubMed    


  225. LAU SCM
    The Value of Comprehensive Molecular Profiling in Early Stage Lung Cancer.
    J Thorac Oncol. 2023;18:393-395.
    PubMed    


  226. LE X
    Resistance to EGFR Inhibitors: Fitness, Competition, and Diversity.
    J Thorac Oncol. 2023;18:390-392.
    PubMed    


  227. VISCA P, Gallo E, Marino M
    New Morphologic Findings Support Invasiveness Criteria in Small-Sized Nonmucinous Lepidic Adenocarcinoma: Commenting a Proposal From the International Association for the Study of Lung Cancer Pathology Committee.
    J Thorac Oncol. 2023;18:387-389.
    PubMed    


  228. MOGHAL N, Li Q, Stewart EL, Navab R, et al
    Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model.
    J Thorac Oncol. 2023;18:499-515.
    PubMed     Abstract available


  229. THUNNISSEN E, Beasley MB, Borczuk A, Dacic S, et al
    Defining Morphologic Features of Invasion in Pulmonary Nonmucinous Adenocarcinoma With Lepidic Growth: A Proposal by the International Association for the Study of Lung Cancer Pathology Committee.
    J Thorac Oncol. 2023;18:447-462.
    PubMed     Abstract available


  230. CHOUDHURY NJ, Marra A, Sui JSY, Flynn J, et al
    Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
    J Thorac Oncol. 2023;18:463-475.
    PubMed     Abstract available


  231. MUTHUSAMY B, Raskina K, Lofgren KT, Li G, et al
    Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma.
    J Thorac Oncol. 2023;18:476-486.
    PubMed     Abstract available


  232. REMON J, Hendriks LEL, Mountzios G, Garcia-Campelo R, et al
    MET alterations in NSCLC-Current Perspectives and Future Challenges.
    J Thorac Oncol. 2023;18:419-435.
    PubMed     Abstract available


    March 2023
  233. DE LEEUW SP, Pruis MA, Sikkema BJ, Mohseni M, et al
    Analysis of serious weight gain in patients using alectinib for ALK positive lung cancer.
    J Thorac Oncol. 2023 Mar 29:S1556-0864(23)00219.
    PubMed     Abstract available


  234. ZHANG H, Nabel CS, Li D, O'Connor RI, et al
    Histone deacetylase 6 inhibition exploits selective metabolic vulnerabilities in LKB1 mutant, KRAS driven non-small cell lung cancer.
    J Thorac Oncol. 2023 Mar 21:S1556-0864(23)00197.
    PubMed     Abstract available


  235. CORNELISSEN R, Prelaj A, Sun S, Baik C, et al
    Poziotinib in Treatment-Naive Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-label Phase 2 Trial (Cohort 4).
    J Thorac Oncol. 2023 Mar 21:S1556-0864(23)00199.
    PubMed     Abstract available


  236. LI Z, Song Z, Zhao Y, Wang P, et al
    D-1553 (garsorasib), a Potent and Selective Inhibitor of KRAS(G12C) in Patients with Non-Small Cell Lung Cancer: Phase I Study Results.
    J Thorac Oncol. 2023 Mar 20:S1556-0864(23)00196.
    PubMed     Abstract available


  237. AKINBOBOLA O, Ray MA, Fehnel C, Saulsberry A, et al
    Institution-Level Evolution of Lung Cancer Resection Quality with Implementation of a Lymph Node Specimen Collection Kit.
    J Thorac Oncol. 2023 Mar 15:S1556-0864(23)00191.
    PubMed     Abstract available


  238. ZHAO J, Zhao L, Guo W, Wang S, et al
    Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients with Resectable Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.
    J Thorac Oncol. 2023 Mar 2:S1556-0864(23)00161.
    PubMed     Abstract available


  239. OU SI, Kim ES
    Response to: Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
    J Thorac Oncol. 2023;18:e30-e31.
    PubMed    


  240. URBANSKA EM, Sorensen JB, Santoni-Rugiu E
    Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
    J Thorac Oncol. 2023;18:e28-e29.
    PubMed    


  241. ZHAO B, Wu J, Ma W
    Neurocognitive Adverse Events in Patients With ALK or ROS1-Positive, Advanced or Metastatic NSCLC Receiving Lorlatinib.
    J Thorac Oncol. 2023;18:e26-e27.
    PubMed    


  242. ZHANG R, Li Y, Chen F, Christiani DC, et al
    Reply to Scott et al: "Gene-Gene interaction in ever-smokers with lung cancer: Is there confounding by COPD in GWAS?".
    J Thorac Oncol. 2023;18:e24-e26.
    PubMed    


  243. YOUNG RP, Scott RJ
    Gene-Gene Interaction in Ever Smokers With Lung Cancer: Is There Confounding by Chronic Obstructive Pulmonary Disease in Genome-Wide Association Studies?
    J Thorac Oncol. 2023;18:e23-e24.
    PubMed    


  244. BORILOVA S, Dusek L, Jakubikova L, Turcani P, et al
    Lung Cancer in the Czech Republic.
    J Thorac Oncol. 2023;18:271-277.
    PubMed    


  245. GIRARD N
    In Patients With Early Stage NSCLC Without Driver Mutation After Surgical Resection and Chemotherapy: Adjuvant Atezolizumab Should Only Be Given for Patients With Programmed Death-Ligand 1 Greater Than or Equal to 50.
    J Thorac Oncol. 2023;18:268-270.
    PubMed    


  246. MARMARELIS ME, Sun L, Aggarwal C
    Adjuvant Atezolizumab Should Be Administered to All Patients With Programmed Death-Ligand 1 Expressing Surgically Resected Stage II to III NSCLC After Chemotherapy: In Favor.
    J Thorac Oncol. 2023;18:265-267.
    PubMed    


  247. RAMELLA S, Soda P
    Stage I Stereotactic Body Radiation Therapy Outcome's Prediction Models: Perfection Is the Enemy of Utility.
    J Thorac Oncol. 2023;18:262-264.
    PubMed    


  248. YEHIA L, Centomo ML, Pandolfi PP, Eng C, et al
    Two's Company, Three's a Crowd: Rb1/Trp53/Pten Trifecta and Lung Cancer Molecular and Histopathologic Heterogeneity.
    J Thorac Oncol. 2023;18:260-261.
    PubMed    


  249. RODEN AC, Molina JR
    Plasma Biomarkers to Monitor Bronchopulmonary Carcinoids-Are We There Yet?
    J Thorac Oncol. 2023;18:257-259.
    PubMed    


  250. FRANK MS, Bodtger U
    An Individualized Approach to Comorbidities in Lung Cancer.
    J Thorac Oncol. 2023;18:254-256.
    PubMed    


  251. KATZ SI, Straus CM, Roshkovan L, Blyth KG, et al
    Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group.
    J Thorac Oncol. 2023;18:278-298.
    PubMed     Abstract available


  252. NISMAN B, Oleinikov K, Nechushtan H, Maimon O, et al
    Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report.
    J Thorac Oncol. 2023;18:369-376.
    PubMed     Abstract available


  253. ZHANG L, Liu C, Zhang B, Zheng J, et al
    PTEN Loss Expands the Histopathologic Diversity and Lineage Plasticity of Lung Cancers Initiated by Rb1/Trp53 Deletion.
    J Thorac Oncol. 2023;18:324-338.
    PubMed     Abstract available


  254. FALKSON CB, Vella ET, Ellis PM, Maziak DE, et al
    Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Systematic Review.
    J Thorac Oncol. 2023;18:299-312.
    PubMed     Abstract available


    February 2023
  255. HE K, Berz D, Gadgeel SM, Iams WT, et al
    MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Non-Squamous Non-Small Cell Lung Cancer Progressing On/After Checkpoint Inhibitor Therapy or Chemotherapy.
    J Thorac Oncol. 2023 Feb 24:S1556-0864(23)00158.
    PubMed     Abstract available


  256. ZHANG Y, Deng C, Zheng Q, Qian B, et al
    Selective mediastinal lymph node dissection strategy for clinical T1N0 invasive lung cancer: A prospective, multicenter, clinical trial.
    J Thorac Oncol. 2023 Feb 23:S1556-0864(23)00138.
    PubMed     Abstract available


  257. ALESSI JV, Elkrief A, Ricciuti B, Wang X, et al
    Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2023 Feb 10:S1556-0864(23)00121.
    PubMed     Abstract available


  258. TRIPHURIDET N, Zhang SS, Nagasaka M, Gao Y, et al
    Low dose computed tomography (LDCT) screening in Asian female never-smokers is as efficacious in detecting lung cancer as in Asian male-ever-smokers: a systematic review and meta-analysis.
    J Thorac Oncol. 2023 Feb 10:S1556-0864(23)00124.
    PubMed     Abstract available


  259. CHEN M, Lu H, Copley SJ, Han Y, et al
    A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity from Programmed Cell Death-1 Pathway Inhibition in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2023 Feb 9:S1556-0864(23)00096.
    PubMed     Abstract available


  260. ASAMURA H, Nishimura KK, Giroux DJ, Chansky K, et al
    IASLC lung cancer staging project: the new database to inform revisions in the ninth edition of the TNM classification of lung cancer.
    J Thorac Oncol. 2023 Feb 9:S1556-0864(23)00097.
    PubMed     Abstract available


  261. IGNATIUS OU SH, Hong JL, Christopoulos P, Lin HM, et al
    Distribution and Detectability of EGFR Exon 20 Insertion Variants in Non-small Cell Lung Cancer.
    J Thorac Oncol. 2023 Feb 2:S1556-0864(23)00095.
    PubMed     Abstract available


  262. HOU X, Zhou C, Wu G, Lin W, et al
    Efficacy, Safety, and Health-Related Quality of Life with Camrelizumab Plus Pemetrexed and Carboplatin as First-Line treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer with Brain Metastases (CAP-BRAIN): A Multicentre, Open-Label, Single-Ar
    J Thorac Oncol. 2023 Feb 2:S1556-0864(23)00092.
    PubMed     Abstract available


  263. PROVENZANO L, Damian S, Duca M, Della Valle S, et al
    Ascites During Selpercatinib Treatment: Need for a Multidisciplinary Approach.
    J Thorac Oncol. 2023;18:e9-e10.
    PubMed    


  264. HEIDEN BT, Puri V
    Response to "Which Factors Determinate the Lymphadenectomy Definition?".
    J Thorac Oncol. 2023;18:e8-e9.
    PubMed    


  265. CHIAPPETTA M, Sassorossi C, Lococo F, Margaritora S, et al
    Which Factors Determinate the Lymphadenectomy Definition? Comment on "Assessment of Updated Commission on Cancer Guidelines for Intraoperative Lymph Node Sampling in Early-Stage Non-Small Cell Lung Cancer".
    J Thorac Oncol. 2023;18:e7-e8.
    PubMed    


  266. ZHANG L, Yang X
    Comment on: "Quitting Smoking at or Around Diagnosis Improves the Overall Survival of Lung Cancer Patients: A Systematic Review and Meta-Analysis".
    J Thorac Oncol. 2023;18:e17-e19.
    PubMed    


  267. HIGASHIYAMA RI, Yoshida T, Yagishita S, Hamada A, et al
    In Response: Letter Received From Dr. Charles Ricordel Titled "Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC".
    J Thorac Oncol. 2023;18:e16-e17.
    PubMed    


  268. PIERRE C, Goter T, Lena H, Le Guen Y, et al
    Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC.
    J Thorac Oncol. 2023;18:e14-e16.
    PubMed    


  269. DE CARLO E, Bertoli E, Chimienti E, Del Conte A, et al
    Chylous Ascites as a Possible Rare Side Effect of Selpercatinib in RET-Positive NSCLC.
    J Thorac Oncol. 2023;18:e11-e13.
    PubMed    


  270. ARTAL-CORTES AF, Verdun-Aguilar J, Marquez-Medina D
    Opening Windows for Thymic Tumors.
    J Thorac Oncol. 2023;18:136-138.
    PubMed    


  271. O'LEARY C, Naidoo J
    PACIFIC in the Real World.
    J Thorac Oncol. 2023;18:133-135.
    PubMed    


  272. TAN WL, Lim DW
    Is There a Unicorn Among the Uncommon EGFR Mutations?
    J Thorac Oncol. 2023;18:129-132.
    PubMed    


  273. NAGASAKA M, Ou SI
    CROWN 2022 Second Interim Updates: When Will Be the Coronation of Lorlatinib?
    J Thorac Oncol. 2023;18:139-142.
    PubMed    


  274. LARSON NB, Oberg AL, Adjei AA, Wang L, et al
    A Clinician's Guide to Bioinformatics for Next-Generation Sequencing.
    J Thorac Oncol. 2023;18:143-157.
    PubMed     Abstract available


  275. MERBOTH F, Nebelung H, Wotschel N, Liebscher H, et al
    Robotic Esophagectomy Compared With Open Esophagectomy Reduces Sarcopenia within the First Postoperative Year: A Propensity Score-Matched Analysis.
    J Thorac Oncol. 2023;18:232-244.
    PubMed     Abstract available


  276. JUNG HA, Kim M, Kim HS, Kim JH, et al
    A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21).
    J Thorac Oncol. 2023;18:223-231.
    PubMed     Abstract available


  277. BAR J, Peled N, Schokrpur S, Wolner M, et al
    UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN).
    J Thorac Oncol. 2023;18:169-180.
    PubMed     Abstract available


  278. GIRARD N, Bar J, Garrido P, Garassino MC, et al
    Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
    J Thorac Oncol. 2023;18:181-193.
    PubMed     Abstract available


  279. YAN W, Zhong WZ, Liu YH, Chen Q, et al
    Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial.
    J Thorac Oncol. 2023;18:194-203.
    PubMed     Abstract available


    January 2023
  280. KILLINGBERG KT, Gronberg BH, Slaaen M, Kirkevold O, et al
    Treatment outcomes of older participants in a randomized trial comparing two schedules of twice-daily thoracic radiotherapy in limited stage small-cell lung cancer.
    J Thorac Oncol. 2023 Jan 27:S1556-0864(23)00016.
    PubMed     Abstract available


  281. MURCIANO-GOROFF YR, Falcon CJ, Lin ST, Chacko C, et al
    Original article: Central nervous system disease in patients with RET fusion-positive non-small cell lung cancer treated with selpercatinib.
    J Thorac Oncol. 2023 Jan 16:S1556-0864(23)00008.
    PubMed     Abstract available


  282. ALDEA M, Marinello A, Duruisseaux M, Zrafi W, et al
    RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion.
    J Thorac Oncol. 2023 Jan 13:S1556-0864(22)01994.
    PubMed     Abstract available


  283. DERCLE L, Fronheiser M, Rizvi NA, Hellmann MD, et al
    Baseline radiomic signature to estimate overall survival in patients with non-small cell lung cancer.
    J Thorac Oncol. 2023 Jan 13:S1556-0864(22)01995.
    PubMed     Abstract available


  284. YANKELEVITZ DF, Yip R, Henschke CI
    Impact of Duration of Diagnostic Workup on Prognosis for Early Lung Cancer.
    J Thorac Oncol. 2023 Jan 12:S1556-0864(22)01996.
    PubMed     Abstract available


  285. KIM DW, Kim SW, Camidge DR, Shu CA, et al
    CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFRm Non-Small-Cell Lung Cancer: A Brief Report.
    J Thorac Oncol. 2023 Jan 11:S1556-0864(22)01997.
    PubMed     Abstract available


  286. KENMOTSU H, Mori K, Nakagawa K, Yamamoto N, et al
    Response to "Letter to the Editor" From David Y. Mak et al.
    J Thorac Oncol. 2023;18:e4-e5.
    PubMed    


  287. MAK DY, Tjong MC, Louie AV
    Usage of Radiotherapy With Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations.
    J Thorac Oncol. 2023;18:e3-e4.
    PubMed    


  288. ZHAO B, Li H, Wu J, Ma W, et al
    Durvalumab After Sequential Chemoradiotherapy Is Safe for Stage III, Unresectable NSCLC: Results From Phase 2 PACIFIC-6 Trial.
    J Thorac Oncol. 2023;18:e1-e2.
    PubMed    


  289. AHN JY, Nagasaka M
    Neptune, the Next Pluto?-Durvalumab and Tremelimumab Face Challenges in Entering the NSCLC Space.
    J Thorac Oncol. 2023;18:29-30.
    PubMed    


  290. JIA K, Ren S
    Neurocognitive Adverse Events of Lorlatinib: On the Way to Precise Prediction?
    J Thorac Oncol. 2023;18:26-28.
    PubMed    


  291. OEZKAN F, Seweryn M, Shukuya T, Owen DH, et al
    Improvement in Survival for Patients With Lung Cancer in Taiwan: Implications and Call to Action.
    J Thorac Oncol. 2023;18:21-25.
    PubMed    


  292. FERRARA R, Ricciuti B, Ambrogio C, Trapani D, et al
    The Anti-Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers.
    J Thorac Oncol. 2023;18:17-20.
    PubMed    


  293. COLORI A, Hiley C
    The Interaction of Preexisting Cardiac Dysfunction and Heart Dose From Radical Radiotherapy on All-Cause Mortality in Locally Advanced NSCLC.
    J Thorac Oncol. 2023;18:14-16.
    PubMed    


  294. BALASUBRAMANIAN A, John T
    Safety of Dueling NSCLC With Dual Agent Immunotherapy.
    J Thorac Oncol. 2023;18:10-13.
    PubMed    


  295. DE CASTRO G JR, Rizvi NA, Schmid P, Syrigos K, et al
    NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
    J Thorac Oncol. 2023;18:106-119.
    PubMed     Abstract available


  296. DAGOGO-JACK I, Abbattista A, Murphy JF, Krulewicz S, et al
    Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
    J Thorac Oncol. 2023;18:67-78.
    PubMed     Abstract available


  297. YANG CY, Lin YT, Lin LJ, Chang YH, et al
    Stage Shift Improves Lung Cancer Survival: Real-World Evidence.
    J Thorac Oncol. 2023;18:47-56.
    PubMed     Abstract available


    December 2022
  298. OSAROGIAGBON RU, Van Schil P, Giroux DJ, Lim E, et al
    The IASLC Lung Cancer Staging Project: Overview of Challenges and Opportunities in Revising the Nodal Classification of Lung Cancer.
    J Thorac Oncol. 2022 Dec 23:S1556-0864(22)01985.
    PubMed     Abstract available


  299. ERNST SM, Mankor J, van Riet J, von der Thusen JH, et al
    Tobacco smoking related mutational signatures in classifying smoking associated and non-smoking associated non-small cell lung cancer.
    J Thorac Oncol. 2022 Dec 14:S1556-0864(22)01961.
    PubMed     Abstract available


  300. DEB D, Moore AC, Basu Roy U
    In Response: Letter Received From Dr. Tadashi Nishimura Titled "What About Palliative and Supportive Care Landscapes?".
    J Thorac Oncol. 2022;17:e95-e96.
    PubMed    


  301. NISHIMURA T
    What About Palliative and Supportive Care Landscapes?
    J Thorac Oncol. 2022;17:e95.
    PubMed    


  302. GROSSO F, Cerbone L, Pasello G
    Pericardial Mesothelioma, a Disease for Brave Hearts.
    J Thorac Oncol. 2022;17:1333-1334.
    PubMed    


  303. BOGART JA
    Immune Checkpoint Inhibition for Locally Advanced NSCLC: Time to Ask New Questions?
    J Thorac Oncol. 2022;17:1330-1332.
    PubMed    


  304. OFFIN M, De Silva DL, Sauter JL, Egger JV, et al
    Multimodality Therapy in Patients With Primary Pericardial Mesothelioma.
    J Thorac Oncol. 2022;17:1428-1432.
    PubMed     Abstract available


  305. LIN EP, Hsu CY, Chiou JF, Berry L, et al
    Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit.
    J Thorac Oncol. 2022;17:1365-1374.
    PubMed     Abstract available


  306. GARASSINO MC, Mazieres J, Reck M, Chouaid C, et al
    Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
    J Thorac Oncol. 2022;17:1415-1427.
    PubMed     Abstract available


    November 2022
  307. FOUSEK K, Horn LA, Qin H, Dahut M, et al
    An IL-15 superagonist enables anti-tumor efficacy of NK cells against all molecular variants of small cell lung cancer (SCLC).
    J Thorac Oncol. 2022 Nov 18:S1556-0864(22)01910.
    PubMed     Abstract available


  308. GARCIA-PARDO M, Chang A, Schmid S, Dong M, et al
    Respiratory and cardiometabolic comorbidities and Stage I-III non-small cell lung cancer (NSCLC) survival: A pooled analysis from the International Lung Cancer Consortium (ILCCO).
    J Thorac Oncol. 2022 Nov 14. pii: S1556-0864(22)01903.
    PubMed     Abstract available


  309. GAO S, Jin L, Meadows HW, Shafman T, et al
    Prediction of distant metastases after stereotactic body radiation therapy for early stage non-small cell lung cancer: development and external validation of a multi-institutional model.
    J Thorac Oncol. 2022 Nov 14. pii: S1556-0864(22)01909.
    PubMed     Abstract available


  310. MITSUDOMI T, Tan D, Yang JC, Ahn MJ, et al
    Expert consensus recommendations on biomarker testing in metastatic and non-metastatic non-small cell lung cancer in Asia.
    J Thorac Oncol. 2022 Nov 12. pii: S1556-0864(22)01905.
    PubMed     Abstract available


    October 2022
  311. WANG Q, Gumus ZH, Colarossi C, Memeo L, et al
    Small Cell Lung Cancer: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening and Early Detection.
    J Thorac Oncol. 2022 Oct 12. pii: S1556-0864(22)01851.
    PubMed     Abstract available


  312. PAIK PK, Fan PD, Qeriqi B, Namakydoust A, et al
    Targeting NFE2L2/KEAP1 mutations in advanced non-small cell lung cancer with the TORC1/2 inhibitor TAK-228.
    J Thorac Oncol. 2022 Oct 11. pii: S1556-0864(22)01825.
    PubMed     Abstract available


  313. HOPKINS AM, Sorich MJ
    Response to Mazzaschi and Buti.
    J Thorac Oncol. 2022;17:e90.
    PubMed    


  314. MAZZASCHI G, Buti S
    What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC?
    J Thorac Oncol. 2022;17:e89-e90.
    PubMed    


  315. SUMI T, Michimata H, Nagayama D, Koshino Y, et al
    Tumor-Associated Raynaud's Phenomenon Exacerbated by Administration of Immune Checkpoint Inhibitors.
    J Thorac Oncol. 2022;17:1233-1234.
    PubMed    


  316. FENG J, Leighl NB
    There Is an Unmet Need for Another Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Inhibitor.
    J Thorac Oncol. 2022;17:1175-1177.
    PubMed    


  317. DAGOGO-JACK I, Piotrowska Z
    There Is No Unmet Need for Another Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Inhibitor for Metastatic NSCLC.
    J Thorac Oncol. 2022;17:1171-1174.
    PubMed    


  318. CANGIR AK, Yumuk PF, Sak SD, Akyurek S, et al
    Lung Cancer in Turkey.
    J Thorac Oncol. 2022;17:1158-1170.
    PubMed    


  319. MOUNTZIOS G, Aggarwal C
    Pembrolizumab Administration Frequency, Dose Exposure, and Toxicity: Is Switching Safe?
    J Thorac Oncol. 2022;17:1155-1157.
    PubMed    


  320. LAU SCM, Ou SI
    And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC.
    J Thorac Oncol. 2022;17:1144-1154.
    PubMed    


    September 2022
  321. SMELTZER MP, Liao W, Faris NR, Fehnel C, et al
    Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening.
    J Thorac Oncol. 2022 Sep 30. pii: S1556-0864(22)01820.
    PubMed     Abstract available


  322. ZHOU C, Huang D, Fan Y, Yu X, et al
    Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial.
    J Thorac Oncol. 2022 Sep 29. pii: S1556-0864(22)01803.
    PubMed     Abstract available


  323. MINO-KENUDSON M, Schalper K, Cooper W, Dacic S, et al
    Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee.
    J Thorac Oncol. 2022 Sep 29. pii: S1556-0864(22)01695.
    PubMed     Abstract available


  324. CRADDOCK M, Nestle U, Koenig J, Schimek-Jasch T, et al
    Cardiac function modifies the impact of heart base dose on survival: A voxel-wise analysis of lung cancer patients from the PET-Plan trial.
    J Thorac Oncol. 2022 Sep 18. pii: S1556-0864(22)01590.
    PubMed    


  325. IGNATIUS OU SH, Nishio M, Ahn MJ, Mok T, et al
    Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study.
    J Thorac Oncol. 2022 Sep 9. pii: S1556-0864(22)01584.
    PubMed     Abstract available


  326. IGNATIUS OU SH
    In Response to Continuation of Lorlatinib Beyond Progressive Disease.
    J Thorac Oncol. 2022;17:e86-e88.
    PubMed    


  327. ZHAO B, Ma W
    Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered.
    J Thorac Oncol. 2022;17:e85-e86.
    PubMed    


  328. BOZINOVSKI S
    Response to "Non-Tumor Cells in Tumor Specimens Impair the Accuracy of qPCR in the Detection of PD-L1 CNV and mRNA Expression".
    J Thorac Oncol. 2022;17:e84-e85.
    PubMed    


  329. ZHANG H, Chen Z, Li M, Sui Q, et al
    Nontumor cells in Tumor Specimens Impair the Accuracy of Quantitative Polymerase Chain Reaction in the Detection of Programmed Death-Ligand 1 Copy Number Variant and mRNA Expression.
    J Thorac Oncol. 2022;17:e83-e84.
    PubMed    


  330. NICHOLSON AG, Scagliotti G, Tsao MS, Yatabe Y, et al
    2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant Classification.
    J Thorac Oncol. 2022;17:e80-e83.
    PubMed    


  331. JAVEY M, Yaung SJ
    Incorporating Genetic Biomarkers in WHO Classification of Lung Cancer.
    J Thorac Oncol. 2022;17:e79-e80.
    PubMed    


  332. ZHAO B, Xing H, Ma W
    Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations.
    J Thorac Oncol. 2022;17:e76-e77.
    PubMed    


  333. LEE J, Hong YS, Cho J, Lee J, et al
    Comment on "Is It Time for a Specific Nodal Assessment for Every NSCLC Stage?"
    J Thorac Oncol. 2022;17:e74-e75.
    PubMed    


  334. CHIAPPETTA M, Sassorossi C, Tabacco D, Lococo F, et al
    Is It Time for a Specific Nodal Assessment for Every NSCLC Stage?
    J Thorac Oncol. 2022;17:e73-e74.
    PubMed    


  335. LEE J, Ahn MJ
    A Response to the Letter to the Editor: "Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic Non-Small Cell Lung Cancer".
    J Thorac Oncol. 2022;17:e72-e73.
    PubMed    


  336. ZHAO B, Li H, Ma W
    Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic NSCLC.
    J Thorac Oncol. 2022;17:e71-e72.
    PubMed    


  337. NIYIBIZI BA, Muhizi E, Ndoli DA, Rukundo I, et al
    Lung Cancer in Rwanda.
    J Thorac Oncol. 2022;17:1074-1077.
    PubMed    


  338. MATSUOKA R, Kawai H, Ito T, Matsubara D, et al
    Determining Whether YAP1 and POU2F3 Are Antineuroendocrine Factors.
    J Thorac Oncol. 2022;17:1070-1073.
    PubMed    


  339. GIRARD N
    EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents.
    J Thorac Oncol. 2022;17:1067-1069.
    PubMed    


  340. WU TC, Lin CC
    Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2022;17:1063-1066.
    PubMed    


  341. KALCHIEM-DEKEL O, Falcon CJ, Bestvina CM, Liu D, et al
    Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.
    J Thorac Oncol. 2022;17:1130-1136.
    PubMed     Abstract available


  342. BAINE MK, Febres-Aldana CA, Chang JC, Jungbluth AA, et al
    POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC.
    J Thorac Oncol. 2022;17:1109-1121.
    PubMed     Abstract available


    August 2022
  343. PAZ-ARES LG, Ciuleanu T, Pluzanski A, Lee JS, et al
    Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
    J Thorac Oncol. 2022 Aug 29. pii: S1556-0864(22)01556.
    PubMed     Abstract available


  344. HEIDEN BT, Eaton DB Jr, Chang SH, Yan Y, et al
    Assessment of Updated Commission on Cancer Guidelines for Intraoperative Lymph Node Sampling in Early-stage Non-small Cell Lung Cancer.
    J Thorac Oncol. 2022 Aug 29. pii: S1556-0864(22)01551.
    PubMed     Abstract available


  345. VACHANI A, Carroll NM, Simoff MJ, Neslund-Dudas C, et al
    Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose CT Screening.
    J Thorac Oncol. 2022 Aug 29. pii: S1556-0864(22)01553.
    PubMed     Abstract available


  346. REDIN E, Garrido-Martin EM, Valencia K, Redrado M, et al
    YES1 is a druggable oncogenic target in Small Cell Lung Cancer.
    J Thorac Oncol. 2022 Aug 18. pii: S1556-0864(22)01530.
    PubMed     Abstract available


  347. SHI Y, Chen G, Wang X, Liu Y, et al
    Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study.
    J Thorac Oncol. 2022 Aug 3. pii: S1556-0864(22)01496.
    PubMed     Abstract available


  348. SMELTZER MP, Ray MA, Faris NR, Osarogiagbon RU, et al
    Genie Out of the Bottle: Is There a Role for Gene-Gene Interactions in Early Detection of Lung Cancer?
    J Thorac Oncol. 2022;17:946-948.
    PubMed    


  349. ROE OD, Creaney J
    Response to "Revisiting 'BAP1ness' in Malignant Pleural Mesothelioma".
    J Thorac Oncol. 2022;17:e69-e70.
    PubMed    


  350. YANG H, Yao F, Peng RW
    Revisiting "BAP1ness" in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2022;17:e67-e69.
    PubMed    


  351. YANG H, Gaudino G, Bardelli F, Carbone M, et al
    Does the Amount of Asbestos Exposure Influence Prognosis?
    J Thorac Oncol. 2022;17:949-952.
    PubMed    


  352. SAVARI O, Chang JC, Bishop JA, Sakthivel MK, et al
    First Report of Thoracic Carcinoma With DEK::AFF2 Rearrangement: A Case Report.
    J Thorac Oncol. 2022;17:1050-1053.
    PubMed     Abstract available


  353. BARBIERI PG, Consonni D, Somigliana A
    Asbestos Lung Burden Does Not Predict Survival in Malignant Pleural Mesothelioma: A Necropsy-Based Study of 185 Cases.
    J Thorac Oncol. 2022;17:1042-1049.
    PubMed     Abstract available


  354. BUCKNELL NW, Belderbos J, Palma DA, Iyengar P, et al
    Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective.
    J Thorac Oncol. 2022;17:961-973.
    PubMed     Abstract available


  355. LAAKSONEN S, Kettunen E, Sutinen E, Ilonen I, et al
    Pulmonary Asbestos Fiber Burden Is Related to Patient Survival in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2022;17:1032-1041.
    PubMed     Abstract available


    July 2022
  356. PASTORINO U, Ladisa V, Trussardo S, Sabia F, et al
    Cytisine therapy improved smoking cessation in the randomized SMILE lung cancer screening trial.
    J Thorac Oncol. 2022 Jul 21. pii: S1556-0864(22)00346.
    PubMed     Abstract available


  357. XIONG A, Ren S, Liu H, Miao L, et al
    Efficacy and safety of SH-1028 in patients with EGFR T790M positive non-small-cell lung cancer: a multicenter, single-arm, open-label, phase 2 trial.
    J Thorac Oncol. 2022 Jul 4. pii: S1556-0864(22)00327.
    PubMed     Abstract available


  358. VOTH PARK J, Chandra R, Cai L, Ganguly D, et al
    Tumor cells modulate macrophage phenotype in a novel in vitro co-culture model of the non-small cell lung cancer tumor microenvironment.
    J Thorac Oncol. 2022 Jul 4. pii: S1556-0864(22)00315.
    PubMed     Abstract available


  359. CAVIC M, Kovacevic T, Zaric B, Stojiljkovic D, et al
    Lung Cancer in Serbia.
    J Thorac Oncol. 2022;17:867-872.
    PubMed    


  360. NIHO S
    Impact of Adding Vascular Endothelial Growth Factor Inhibitor to Immune Checkpoint Inhibitor Therapy.
    J Thorac Oncol. 2022;17:865-866.
    PubMed    


  361. GHAFOOR A, Hassan R
    Somatic BAP1 Loss as a Predictive Biomarker of Overall Survival in Patients With Malignant Pleural Mesothelioma Treated With Chemotherapy.
    J Thorac Oncol. 2022;17:862-864.
    PubMed    


  362. LOUW A, Panou V, Szejniuk WM, Meristoudis C, et al
    BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
    J Thorac Oncol. 2022;17:921-930.
    PubMed     Abstract available


  363. CARBONE M, Pass HI, Ak G, Alexander HR Jr, et al
    Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.
    J Thorac Oncol. 2022;17:873-889.
    PubMed     Abstract available


  364. HIGASHIYAMA RI, Yoshida T, Yagishita S, Ohuchi M, et al
    Safety implications of switching pembrolizumab dosage from 200 mg Q3W to 400 mg Q6W in patients with advanced non-small-cell lung cancer.
    J Thorac Oncol. 2022 Jul 1. pii: S1556-0864(22)00314.
    PubMed     Abstract available


    June 2022
  365. FERNANDEZ AI, Gavrielatou N, McCann L, Shafi S, et al
    PD-L1 and PD-L2 mRNA measured using closed system qRT-PCR are associated with outcome and high negative predictive value in immunotherapy-treated non-small cell lung cancer.
    J Thorac Oncol. 2022 Jun 25. pii: S1556-0864(22)00311.
    PubMed     Abstract available


  366. RECK M, Mok TSK, Mansfield A, De Boer R, et al
    Brief Report: Exploratory analysis of maintenance therapy in patients with extensive-stage small cell lung cancer treated first-line with atezolizumab plus carboplatin and etoposide.
    J Thorac Oncol. 2022 Jun 25. pii: S1556-0864(22)00300.
    PubMed     Abstract available


  367. HIBINO M, Uryu K, Takeda T, Kunimatsu Y, et al
    Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.
    J Thorac Oncol. 2022 Jun 22. pii: S1556-0864(22)00295.
    PubMed     Abstract available


  368. LU S, Zhang Y, Zhang G, Zhou J, et al
    Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study.
    J Thorac Oncol. 2022 Jun 17. pii: S1556-0864(22)00297.
    PubMed     Abstract available


  369. CARDONA AF, Mejia SA, Viola L, Chamorro DF, et al
    Lung Cancer in Colombia.
    J Thorac Oncol. 2022 Jun 15. pii: S1556-0864(22)00217.
    PubMed    


  370. NGUYEN EM, Taniguchi H, Chan JM, Zhan YA, et al
    Targeting LSD1 rescues MHC class I antigen presentation and overcomes PD-L1 blockade resistance in small cell lung cancer.
    J Thorac Oncol. 2022 Jun 9. pii: S1556-0864(22)00273.
    PubMed     Abstract available


  371. RICCIUTI B, Awad MM
    Reply to Kus and Aktas.
    J Thorac Oncol. 2022;17:e64-e65.
    PubMed    


  372. KUS T, Aktas G
    Letter to the Editor Concerning Diminished Efficacy of Programmed Death-(Ligand) 1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    J Thorac Oncol. 2022;17:e63-e64.
    PubMed    


  373. MOK T
    In Response to Outcomes by ALK Status (Immunohistochemistry or Fluorescence In Situ Hybridization) in ALEX.
    J Thorac Oncol. 2022;17:e62-e63.
    PubMed    


  374. LI M
    Outcomes by ALK Status (Immunohistochemistry or Fluorescence In Situ Hybridization) in ALEX.
    J Thorac Oncol. 2022;17:e61-e62.
    PubMed    


  375. CANDAL-PEDREIRA C, Ruano-Ravina A, Provencio M, Fernandez-Villar A, et al
    Does the Age of Inclusion in Lung Cancer Screening Studies Overestimate the Benefits?
    J Thorac Oncol. 2022;17:e59-e61.
    PubMed    


  376. SALEH MM, Scheffler M, Merkelbach-Bruse S, Wolf J, et al
    Reply to: "Survival Analysis of TP53 Co-Mutations Should be Interpreted More Cautiously".
    J Thorac Oncol. 2022;17:e57-e59.
    PubMed    


  377. BRADA M, Forbes H, Ashley S, Fenwick J, et al
    Robust Comprehensive Dataset Provides Pause for Thought.
    J Thorac Oncol. 2022;17:e56-e57.
    PubMed    


  378. SALEM A, Franks K, Greystoke A, Hanna GG, et al
    Unaccounted Confounders Limit the Ability to Draw Conclusions From Big Data Analysis Comparing Radiotherapy Fractionation Regimens in NSCLC.
    J Thorac Oncol. 2022;17:e55-e56.
    PubMed    


  379. WRIGHT GM, Goodwin D
    Response to Letter: Beyond "Personalized" to "Tumoralized" Therapy.
    J Thorac Oncol. 2022;17:e54.
    PubMed    


  380. GOTO T
    Beyond Personalized to "Tumoralized" Therapy.
    J Thorac Oncol. 2022;17:e53-e54.
    PubMed    


  381. FROST N, Griesinger F, Hoffmann H, Langer F, et al
    Lung Cancer in Germany.
    J Thorac Oncol. 2022;17:742-750.
    PubMed    


  382. CORTELLINI A, Facchinetti F, Derosa L, Pinato DJ, et al
    Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone Matters.
    J Thorac Oncol. 2022;17:739-741.
    PubMed    


  383. ATAY SM, Kim AW
    Possibly Two Birds or One Squirrel.
    J Thorac Oncol. 2022;17:737-738.
    PubMed    


  384. RITTBERG R, Abraham N, Laskin J, Ho C, et al
    Hyper-Sensitive? Targeted Therapy With a Primed Immune System.
    J Thorac Oncol. 2022;17:734-736.
    PubMed    


  385. VOKES NI, Chambers E, Nguyen T, Coolidge A, et al
    Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
    J Thorac Oncol. 2022;17:779-792.
    PubMed     Abstract available


  386. RUFFINI E, Rami-Porta R, Huang J, Ahmad U, et al
    The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors.
    J Thorac Oncol. 2022;17:838-851.
    PubMed     Abstract available


  387. SHIN DW, Cho JH, Ha J, Jung KW, et al
    Trends in Incidence and Survival of Patients With Thymic Epithelial Tumor in a High-Incidence Asian Country: Analysis of the Korean Central Cancer Registry 1999 to 2017.
    J Thorac Oncol. 2022;17:827-837.
    PubMed     Abstract available


  388. SHI Y, Li B, Wu L, Pan Y, et al
    Efficacy and safety of Limertinib (ASK120067) in patients with locally advanced or metastatic EGFR T790M mutated non-small cell lung cancer: a multicenter, single-arm, phase 2b study.
    J Thorac Oncol. 2022 Jun 1. pii: S1556-0864(22)00267.
    PubMed     Abstract available


  389. PICCIRILLO MC, Bonanno L, Garassino MC, Esposito G, et al
    Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small cell lung cancer. The BEVERLY multicenter randomized phase III trial.
    J Thorac Oncol. 2022 Jun 1. pii: S1556-0864(22)00268.
    PubMed     Abstract available


    May 2022
  390. KENMOTSU H, Wakuda K, Mori K, Kato T, et al
    Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study.
    J Thorac Oncol. 2022 May 27. pii: S1556-0864(22)00265.
    PubMed     Abstract available


  391. ZHANG F, Guo W, Zhou B, Wang S, et al
    Research article: Three-year Follow-up of Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2022 May 9. pii: S1556-0864(22)00216.
    PubMed     Abstract available


  392. SHEIKH HS, Munawar K, Sheikh F, Qamar MFU, et al
    Lung Cancer in Pakistan.
    J Thorac Oncol. 2022;17:602-607.
    PubMed    


  393. POLERI C
    Sex-Based Differences in Lung Cancer: Does It Matter?
    J Thorac Oncol. 2022;17:599-601.
    PubMed    


  394. EVANS WK, Warren GW, Dresler C
    Ignoring the Obvious: Smoking Cessation Improves Survival.
    J Thorac Oncol. 2022;17:596-598.
    PubMed    


  395. WOODARD GA, Cho C, Chen L
    Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?
    J Thorac Oncol. 2022;17:592-595.
    PubMed    


  396. ZHANG C, Wu YL, Zhong WZ
    New Normal for Lung Cancer Clinical Trials Under Coronavirus Disease 2019.
    J Thorac Oncol. 2022;17:588-591.
    PubMed    


  397. FUJIKAWA R, Muraoka Y, Kashima J, Yoshida Y, et al
    Clinicopathologic and Genotypic Features of Lung Adenocarcinoma Characterized by the International Association for the Study of Lung Cancer Grading System.
    J Thorac Oncol. 2022;17:700-707.
    PubMed     Abstract available


  398. RODEN AC, Ahmad U, Cardillo G, Girard N, et al
    Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group.
    J Thorac Oncol. 2022;17:637-650.
    PubMed     Abstract available


  399. AUJLA S, Aloe C, Vannitamby A, Hendry S, et al
    Programmed Death-Ligand 1 Copy Number Loss in NSCLC Associates With Reduced Programmed Death-Ligand 1 Tumor Staining and a Cold Immunophenotype.
    J Thorac Oncol. 2022;17:675-687.
    PubMed     Abstract available


  400. SAUTER JL, Dacic S, Galateau-Salle F, Attanoos RL, et al
    The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
    J Thorac Oncol. 2022;17:608-622.
    PubMed     Abstract available


    April 2022
  401. ZHANG R, Shen S, Wei Y, Zhu Y, et al
    A large-scale genome-wide gene-gene interaction study of lung cancer susceptibility in Europeans with a trans-ethnic validation in Asians.
    J Thorac Oncol. 2022 Apr 29. pii: S1556-0864(22)00215.
    PubMed     Abstract available


  402. MOUTAFI M, Martinez-Morilla S, Divakar P, Vathiotis I, et al
    Discovery of biomarkers of resistance to immune checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling.
    J Thorac Oncol. 2022 Apr 28. pii: S1556-0864(22)00212.
    PubMed     Abstract available


  403. DEB D, Moore AC, Roy UB
    2021 global lung cancer therapy landscape.
    J Thorac Oncol. 2022 Apr 27. pii: S1556-0864(22)00211.
    PubMed     Abstract available


  404. LEE J, Hong YS, Cho J, Lee J, et al
    Reclassifying the IASLC R Classification According to the Extent of Nodal Dissection for Non-Small Cell Lung Cancer: One Size Does Not Fit All.
    J Thorac Oncol. 2022 Apr 21. pii: S1556-0864(22)00195.
    PubMed     Abstract available


  405. LEE J, Koh J, Kim HK, Hong S, et al
    Bevacizumab plus atezolizumab following progression on atezolizumab monotherapy in pretreated non-small cell lung cancer patients: An open-label, two-stage, phase II trial.
    J Thorac Oncol. 2022 Apr 12. pii: S1556-0864(22)00193.
    PubMed     Abstract available


  406. ELHASSAN MMA, Mohamedani AA, Mohamed SAH, Hamdoun AOA, et al
    Lung Cancer in Sudan.
    J Thorac Oncol. 2022;17:489-498.
    PubMed    


  407. REGUART N, Reyes R
    Spotlight on Camrelizumab in Advanced Squamous Lung Cancer: Another Feather in the Cap of Chinese Checkpoint Inhibitors.
    J Thorac Oncol. 2022;17:477-480.
    PubMed    


  408. YANG SR, Rekhtman N
    Molecular Testing Identifies Ultra-Late Recurrences in Lung Carcinomas: Implications for Clinical Management.
    J Thorac Oncol. 2022;17:e50-e51.
    PubMed    


  409. GOTO T
    Genomically Metastatic, but Surgically Curable?
    J Thorac Oncol. 2022;17:e49-e50.
    PubMed    


  410. LIN Y, Fu M, Inoue K, Jeon CY, et al
    Response to Letter to the Editor.
    J Thorac Oncol. 2022;17:e47-e48.
    PubMed    


  411. TANG W, Lu L, Gu JW, Chen HL, et al
    Some Thoughts Concerning the Patient Adherence to Lung Computed Tomography Screening Reporting and Data System-Recommended Screening Intervals.
    J Thorac Oncol. 2022;17:e45-e46.
    PubMed    


  412. ROSNER S, Forde PM
    Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC.
    J Thorac Oncol. 2022;17:503-509.
    PubMed    


  413. HENDRIKS LEL, Remon J, Reck M
    Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC.
    J Thorac Oncol. 2022;17:499-502.
    PubMed    


  414. PUTORA PM, De Ruysscher DK
    Is Hypofractionation a Good Idea in Radiotherapy for Locally Advanced NSCLC?
    J Thorac Oncol. 2022;17:487-488.
    PubMed    


  415. WANG F, Zhou Q
    The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC.
    J Thorac Oncol. 2022;17:481-486.
    PubMed    


  416. OU SI, Solomon BJ, Shaw AT, Gadgeel SM, et al
    Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
    J Thorac Oncol. 2022;17:568-577.
    PubMed     Abstract available


  417. FOLCH EE, Bowling MR, Pritchett MA, Murgu SD, et al
    NAVIGATE 24-Month Results: Electromagnetic Navigation Bronchoscopy for Pulmonary Lesions at 37 Centers in Europe and the United States.
    J Thorac Oncol. 2022;17:519-531.
    PubMed     Abstract available


  418. MALESZEWSKI JJ, Basso C, Bois MC, Glass C, et al
    The 2021 WHO Classification of Tumors of the Heart.
    J Thorac Oncol. 2022;17:510-518.
    PubMed    


    March 2022
  419. SCALERA S, Mazzotta M, Cortile C, Krasniqi E, et al
    Concise Review: Gene of The Month KEAP1-mutant non-small cell lung cancer: the catastrophic failure of a cell-protecting hub.
    J Thorac Oncol. 2022 Mar 26. pii: S1556-0864(22)00166.
    PubMed     Abstract available


  420. JAIN D, Nambirajan A, Chen G, Geisinger K, et al
    Non-small cell lung carcinoma subtyping in conventional cytology: Results of the IASLC Cytology Working Group survey to determine specific cytomorphological criteria for adenocarcinoma and squamous cell carcinoma.
    J Thorac Oncol. 2022 Mar 21. pii: S1556-0864(22)00145.
    PubMed     Abstract available


  421. LU S, Zhou Q, Liu X, Du Y, et al
    Lorlatinib for Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer: Primary Efficacy and Safety From a Phase 2 Study in China.
    J Thorac Oncol. 2022 Mar 17. pii: S1556-0864(22)00147.
    PubMed     Abstract available


  422. DETTERBECK FC, Nishimura KK, Cilento VJ, Giuliani M, et al
    The IASLC Lung Cancer Staging Project: Methods and Guiding Principles for the Development of the 9(th) Edition TNM Classification.
    J Thorac Oncol. 2022 Mar 9. pii: S1556-0864(22)00107.
    PubMed     Abstract available


  423. SCALERA S, Mazzotta M, Cappuzzo F, Ciliberto G, et al
    KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously".
    J Thorac Oncol. 2022;17:e40-e41.
    PubMed    


  424. HORINOUCHI H, Kusumoto M, Yatabe Y, Aokage K, et al
    Lung Cancer in Japan.
    J Thorac Oncol. 2022;17:353-361.
    PubMed    


  425. TEN HAAF K
    Informing Patient Surveillance for the Growing Number of Survivors of Lung Cancer.
    J Thorac Oncol. 2022;17:345-347.
    PubMed    


  426. PELOSI G
    Labeling Lung Neuroendocrine Neoplasms for Ki-67 Antigen to Score a Bull's-Eye, Not Shoot in the Dark.
    J Thorac Oncol. 2022;17:e41-e44.
    PubMed    


  427. LE X, Heymach J
    In Response.
    J Thorac Oncol. 2022;17:e39.
    PubMed    


  428. FERRARA R, Milani M, Garassino MC, Colombo MP, et al
    Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction?
    J Thorac Oncol. 2022;17:e35-e38.
    PubMed    


  429. FAN C, Zhao Q, Teng C, Jiang Z, et al
    Response to Letter to the Editor Titled "Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases from NSCLC?"
    J Thorac Oncol. 2022;17:e33-e34.
    PubMed    


  430. PAN Z
    Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases From NSCLC.
    J Thorac Oncol. 2022;17:e31-e32.
    PubMed    


  431. ZHANG Y, Deng C, Zheng Q, Li Y, et al
    The Grading System of Lung Adenocarcinoma: Ever-Evolving Concepts.
    J Thorac Oncol. 2022;17:e30.
    PubMed    


  432. LI S, Deng J, She Y, Hou L, et al
    Clinical Thoughts on the Predictive Value of the Newly Proposed Grading System of Invasive Pulmonary Adenocarcinoma.
    J Thorac Oncol. 2022;17:e28-e29.
    PubMed    


  433. LIN Y, Fu M, Inoue K, Jeon CY, et al
    Response to Letter to the Editor.
    J Thorac Oncol. 2022;17:e27-e28.
    PubMed    


  434. RAJAGOPAL MS, Senthilnathan R, Km G, Ram M R, et al
    Conceptual and Statistical Interpretation of a Systematic Review and Meta-Analysis on Patient Adherence to Lung-RADS-Recommended Screening Intervals in the United States.
    J Thorac Oncol. 2022;17:e25-e27.
    PubMed    


  435. DZIADZIUSZKO R
    STK11 and KEAP1 Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues.
    J Thorac Oncol. 2022;17:351-352.
    PubMed    


  436. CAMIDGE DR
    The Magic of ADAURA?
    J Thorac Oncol. 2022;17:348-350.
    PubMed    


  437. LU S, Li Z
    Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade.
    J Thorac Oncol. 2022;17:341-344.
    PubMed    


  438. TSAO MS, Nicholson AG, Maleszewski JJ, Marx A, et al
    Reprint of "Introduction to 2021 WHO Classification of Thoracic Tumors".
    J Thorac Oncol. 2022;17:337-340.
    PubMed    


  439. NICHOLSON AG, Tsao MS, Beasley MB, Borczuk AC, et al
    The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015.
    J Thorac Oncol. 2022;17:362-387.
    PubMed     Abstract available


  440. LU S, Wang Q, Zhang G, Dong X, et al
    Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
    J Thorac Oncol. 2022;17:411-422.
    PubMed     Abstract available


  441. KOSARI F, Disselhorst M, Yin J, Peikert T, et al
    Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors.
    J Thorac Oncol. 2022;17:446-454.
    PubMed     Abstract available


  442. RICCIUTI B, Arbour KC, Lin JJ, Vajdi A, et al
    Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    J Thorac Oncol. 2022;17:399-410.
    PubMed     Abstract available


  443. WU YL, John T, Grohe C, Majem M, et al
    Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
    J Thorac Oncol. 2022;17:423-433.
    PubMed     Abstract available


  444. OFFIN M, Yang SR, Egger J, Jayakumaran G, et al
    Molecular Characterization of Peritoneal Mesotheliomas.
    J Thorac Oncol. 2022;17:455-460.
    PubMed     Abstract available


  445. HU ZI, Miettinen M, Quezado M, Lebensohn AP, et al
    Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.
    J Thorac Oncol. 2022;17:461-466.
    PubMed     Abstract available


    February 2022
  446. MCCOACH CE, Rolfo C, Drilon A, Lacouture M, et al
    Hypersensitivity Reactions to Selpercatinib Treatment with or Without Prior Immune Checkpoint Inhibitor Therapy in Patients with Non-Small-Cell Lung Cancer in LIBRETTO-001.
    J Thorac Oncol. 2022 Feb 17. pii: S1556-0864(22)00094.
    PubMed     Abstract available


  447. HOPKINS AM, Badaoui S, Kichenadasse G, Karapetis CS, et al
    Efficacy of atezolizumab in patients with advanced non-small cell lung cancer receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomised control trials.: Proton pump inhibitors, antibiotics, and immunothera
    J Thorac Oncol. 2022 Feb 17. pii: S1556-0864(22)00093.
    PubMed     Abstract available


  448. SMELTZER MP, Scagliotti GV, Wakelee HA, Mitsudomi T, et al
    International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials.
    J Thorac Oncol. 2022 Feb 15. pii: S1556-0864(22)00086.
    PubMed     Abstract available


  449. AHN MJ, Cho BC, Ou X, Walding A, et al
    Brief Report: Osimertinib Plus Durvalumab in Patients with EGFR-Mutated, Advanced Non-Small Cell Lung Cancer: A Phase 1b, Open-Label, Multicenter Trial.
    J Thorac Oncol. 2022 Feb 15. pii: S1556-0864(22)00081.
    PubMed     Abstract available


  450. SHI Y, Zhao Y, Yang S, Zhou J, et al
    Safety, Efficacy and Pharmacokinetics of Rezivertinib (BPI-7711) in Advanced Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation: a Phase 1 Dose-Escalation and Dose-Expansion Study.
    J Thorac Oncol. 2022 Feb 15. pii: S1556-0864(22)00084.
    PubMed     Abstract available


  451. YU XQ, Yap ML, Cheng ES, Ngo PJ, et al
    Evaluating prognostic factors for sex differences in lung cancer survival: findings from a large Australian cohort.
    J Thorac Oncol. 2022 Feb 3. pii: S1556-0864(22)00085.
    PubMed    


  452. KERPEL-FRONIUS A, Tammemagi MC, Cavic M, Huber RM, et al
    Lung Cancer Screening in Persons Who Never Smoked Has to be Evaluated-A Response to Letter to the Editor.
    J Thorac Oncol. 2022;17:e20-e21.
    PubMed    


  453. FU F, Zhang Y, He N, Chen H, et al
    Emerging High-Risk Population of Lung Cancer: To Reveal the Unrevealed.
    J Thorac Oncol. 2022;17:e18-e20.
    PubMed    


  454. NAVANI N, Baldwin DR, Edwards JG, Evison M, et al
    Lung Cancer in the United Kingdom.
    J Thorac Oncol. 2022;17:186-193.
    PubMed    


  455. DERKS JL, Dingemans AC, Speel EM
    Molecular Knowledge and Clinical Relevance - Stepping Stones in Improving Classification of Lung Neuroendocrine Neoplasms.
    J Thorac Oncol. 2022;17:e8-e10.
    PubMed    


  456. PELOSI G
    The Natural History in Lung Neuroendocrine Neoplasms: The Stone Guest Who Matters.
    J Thorac Oncol. 2022;17:e5-e8.
    PubMed    


  457. MOONEN L, Derks JL, Dingemans AC, Speel EJM, et al
    Preoperative Biopsy Diagnosis in Patients With Pulmonary Carcinoids: A Biomarker Panel Will Be Crucial to Hit a Bull's Eye.
    J Thorac Oncol. 2022;17:e21-e23.
    PubMed    


  458. LIN A, Luo P, Zhang J
    Survival Analysis of TP53 Comutations Should Be Interpreted More Cautiously.
    J Thorac Oncol. 2022;17:e14-e18.
    PubMed    


  459. THOMAS NJ, Myall NJ, Sun F, Patil T, et al
    In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"
    J Thorac Oncol. 2022;17:e12-e14.
    PubMed    


  460. NARDONE V, Correale P, Mutti L, Desideri I, et al
    Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?
    J Thorac Oncol. 2022;17:e10-e12.
    PubMed    


  461. FAIVRE-FINN C, Edwards JG, Hatton M
    Postoperative Radiation Therapy Should Not Be Used for the Therapy of Stage III-N2 NSCLC.
    J Thorac Oncol. 2022;17:197-199.
    PubMed    


  462. LIU J, Ladbury C, Kim J, Raz D, et al
    Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients.
    J Thorac Oncol. 2022;17:194-196.
    PubMed    


  463. NAGASAKA M, Ou SI
    Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy.
    J Thorac Oncol. 2022;17:182-185.
    PubMed    


  464. MUTHUSAMY B, Pennell N
    Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer.
    J Thorac Oncol. 2022;17:179-181.
    PubMed    


  465. LIN YT, Shih JY
    Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors in NSCLC: Two Heads Are Better Than One.
    J Thorac Oncol. 2022;17:176-178.
    PubMed    


  466. LASVERGNAS J, Playe M, Saint-Val L, Brillet PY, et al
    Pitfalls in Cancer Evaluation in Case of Chronic Superior Vena Cava Obstruction: Vertebral Enhancement and Hot Quadrate Sign in the Liver.
    J Thorac Oncol. 2022;17:324-326.
    PubMed    


  467. MARX A, Chan JKC, Chalabreysse L, Dacic S, et al
    The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?
    J Thorac Oncol. 2022;17:200-213.
    PubMed     Abstract available


  468. NOGAMI N, Barlesi F, Socinski MA, Reck M, et al
    IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
    J Thorac Oncol. 2022;17:309-323.
    PubMed     Abstract available


    January 2022
  469. BRADA M, Forbes H, Ashley S, Fenwick J, et al
    Improving outcomes in non-small cell lung cancer; optimum dose fractionation in radical radiotherapy matters.
    J Thorac Oncol. 2022 Jan 26. pii: S1556-0864(22)00051.
    PubMed     Abstract available


  470. WHISENANT JG, Baena J, Cortellini A, Huang LC, et al
    A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry.
    J Thorac Oncol. 2022 Jan 24. pii: S1556-0864(22)00033.
    PubMed     Abstract available


  471. SHILPAKAR R, Paudel BD, Sharma R, Silwal SR, et al
    Lung Cancer in Nepal.
    J Thorac Oncol. 2022;17:22-29.
    PubMed    


  472. MASAGO K, Fujita S
    Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment.
    J Thorac Oncol. 2022;17:16-18.
    PubMed    


  473. SALLOUM RG, Braithwaite D
    Expansion of Guideline-Recommended Lung Cancer Screening Eligibility: Implications for Health Equity of Joint Screening and Cessation Interventions.
    J Thorac Oncol. 2022;17:13-15.
    PubMed    


  474. TSAO MS, Nicholson AG, Maleszewski JJ, Marx A, et al
    Introduction to 2021 WHO Classification of Thoracic Tumors.
    J Thorac Oncol. 2022;17:e1-e4.
    PubMed    


  475. FENNELL DA, Dulloo S
    Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.
    J Thorac Oncol. 2022;17:34-37.
    PubMed    


  476. BAAS P
    Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.
    J Thorac Oncol. 2022;17:30-33.
    PubMed    


  477. JOUBERT P, Travis WD
    Prognostic Impact of Ground-Glass Opacity/Lepidic Component in Pulmonary Adenocarcinoma: A Hazy Staging Dilemma.
    J Thorac Oncol. 2022;17:19-21.
    PubMed    


  478. YAMAMOTO H, Togashi Y
    Programmed Death-Ligand 1-Rich Premetastatic Niche in Adjuvant Chemotherapy.
    J Thorac Oncol. 2022;17:10-12.
    PubMed    


  479. GROSS DJ, Chintala NK, Vaghjiani RG, Grosser R, et al
    Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma.
    J Thorac Oncol. 2022;17:89-102.
    PubMed     Abstract available


  480. OKUBO Y, Kashima J, Teishikata T, Muraoka Y, et al
    Prognostic Impact of the Histologic Lepidic Component in Pathologic Stage IA Adenocarcinoma.
    J Thorac Oncol. 2022;17:67-75.
    PubMed     Abstract available


  481. LIN Y, Fu M, Ding R, Inoue K, et al
    Patient Adherence to Lung CT Screening Reporting & Data System-Recommended Screening Intervals in the United States: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2022;17:38-55.
    PubMed     Abstract available


    December 2021
  482. CHO BC, Han JY, Kim SW, Lee KH, et al
    A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2021 Dec 24. pii: S1556-0864(21)03403.
    PubMed     Abstract available


  483. CAINI S, Del Riccio M, Vettori V, Scotti V, et al
    Quitting smoking at or around diagnosis improves the overall survival of lung cancer patients: a systematic review and meta-analysis.
    J Thorac Oncol. 2021 Dec 17. pii: S1556-0864(21)03404.
    PubMed     Abstract available


  484. REN S, Chen J, Xu X, Jiang T, et al
    Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous non-small-cell lung cancer (CameL-sq): a phase 3 trial.
    J Thorac Oncol. 2021 Dec 16. pii: S1556-0864(21)03392.
    PubMed     Abstract available


  485. EBERL M, Tanaka LF, Kraywinkel K, Klug SJ, et al
    Incidence of smoking-related second primary cancers after lung cancer in Germany: an analysis of nationwide cancer registry data.
    J Thorac Oncol. 2021 Dec 10. pii: S1556-0864(21)03390.
    PubMed     Abstract available


  486. HUBER RM, Cavic M, Kerpel-Fronius A, Viola L, et al
    Lung Cancer Screening Considerations During Respiratory Infection Outbreaks, Epidemics or Pandemics: An IASLC Early Detection and Screening Committee Report.
    J Thorac Oncol. 2021 Dec 2. pii: S1556-0864(21)03326.
    PubMed     Abstract available


  487. PARK S, Choi CM, Hwang SS, Choi YL, et al
    Lung Cancer in Korea.
    J Thorac Oncol. 2021;16:1988-1993.
    PubMed    


  488. BIAN Y, Liang J, Shan G, Zhan C, et al
    Combining Clinical and Molecular Characteristics to Precisely Predict the Prognosis of Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:e99-e100.
    PubMed    


  489. KUMAR A, Kumar S, Gilja S, Potter A, et al
    Encouraging Guideline-Concordant Treatment for T3 NSCLC.
    J Thorac Oncol. 2021;16:e98-e99.
    PubMed    


  490. LI M, Liang J, Bi G, Zhan C, et al
    Could T3Satell Tumors Be Considered Reclassified as T2b?
    J Thorac Oncol. 2021;16:e97-e98.
    PubMed    


  491. MORGENSZTERN D, Govindan R
    Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation.
    J Thorac Oncol. 2021;16:1999-2001.
    PubMed    


  492. AREDO JV, Hellyer JA, Neal JW, Wakelee HA, et al
    Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1994-1998.
    PubMed    


  493. BELDA-SANCHIS J, Trujillo-Reyes JC, Martinez-Tellez E, Cladellas-Gutierrez E, et al
    Brain Metastasis From Thymic Epithelial Tumors: Strengthening the Evidence, a Call for Action.
    J Thorac Oncol. 2021;16:1984-1987.
    PubMed    


  494. PELOSI G
    KEAP1 and TP53 (Co)mutation in Lung Adenocarcinoma: Another Bullet for Immunotherapy?
    J Thorac Oncol. 2021;16:1979-1983.
    PubMed    


  495. BUGLIONI S, Marino M
    Pitfalls in Molecular Testing and the Added Value of the Cancer Research Biomedical Community.
    J Thorac Oncol. 2021;16:1976-1978.
    PubMed    


  496. BENITEZ JC, Boucher ME, Dansin E, Kerjouan M, et al
    Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMIC.
    J Thorac Oncol. 2021;16:2144-2149.
    PubMed     Abstract available


  497. SCALERA S, Mazzotta M, Corleone G, Sperati F, et al
    KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
    J Thorac Oncol. 2021;16:2065-2077.
    PubMed     Abstract available


  498. TEISHIKATA T, Shiraishi K, Shinno Y, Kobayashi Y, et al
    An Alert to Possible False Positives With a Commercial Assay for MET Exon 14 Skipping.
    J Thorac Oncol. 2021;16:2133-2138.
    PubMed     Abstract available


  499. YANG Y, Sun J, Wang Z, Fang J, et al
    Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
    J Thorac Oncol. 2021;16:2109-2120.
    PubMed     Abstract available


    November 2021
  500. LEIGHL NB, Laurie SA, Goss GD, Hughes BGM, et al
    CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.
    J Thorac Oncol. 2021 Nov 17. pii: S1556-0864(21)03322.
    PubMed     Abstract available


  501. ROLFO C, Meshulami N, Russo A, Krammer F, et al
    Lung Cancer and SARS-CoV-2 infection: Identifying important knowledge gaps for investigation.
    J Thorac Oncol. 2021 Nov 10. pii: S1556-0864(21)03309.
    PubMed     Abstract available


  502. GOUNANT V, Ferre VM, Soussi G, Charpentier C, et al
    Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses.
    J Thorac Oncol. 2021 Nov 2. pii: S1556-0864(21)03286.
    PubMed     Abstract available


  503. STOCK-MARTINEAU S, Shepherd FA
    EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1793-1797.
    PubMed    


  504. MOORE S, Wheatley-Price P
    EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1788-1792.
    PubMed    


  505. YANG C, Li Y, Xiao SY
    Do We Really Understand the Relationship Between Expression of ACE2 and Coronavirus Disease 2019 Lung Pathophysiology?
    J Thorac Oncol. 2021;16:1785-1787.
    PubMed    


  506. LOPEZ-CASTRO R, Recondo G, Gorria T, Mezquita L, et al
    A New Pretreatment Mesothelioma Risk Score: Integrating Clinical and Molecular Factors for Predicting Outcomes in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:1782-1784.
    PubMed    


  507. ZHU VW, Ou SI
    Ensartinib (X-396), an Approved ALK Inhibitor, Falls Out as a Clinically Relevant ROS1 Inhibitor.
    J Thorac Oncol. 2021;16:1778-1781.
    PubMed    


  508. ADJEI AA
    Tackling the High Cost of Oncology Drugs.
    J Thorac Oncol. 2021;16:1774-1777.
    PubMed    


  509. DE BAERE T, Woodrum D, Tselikas L, Abtin F, et al
    The ECLIPSE Study: Efficacy of Cryoablation on Metastatic Lung Tumors With a 5-Year Follow-Up.
    J Thorac Oncol. 2021;16:1840-1849.
    PubMed     Abstract available


  510. MIKUBO M, Inoue Y, Liu G, Tsao MS, et al
    Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy.
    J Thorac Oncol. 2021;16:1798-1809.
    PubMed     Abstract available


  511. VAN DEN BROEK MFM, Levy S, Buikhuisen WA, Dijke K, et al
    Well-Differentiated Bronchopulmonary Neuroendocrine Tumors: More Than One Entity.
    J Thorac Oncol. 2021;16:1810-1820.
    PubMed     Abstract available


  512. CHIAPPETTA M, Lococo F, Zanfrini E, Moroni R, et al
    The International Thymic Malignancy Interest Group Classification of Thymoma Recurrence: Survival Analysis and Perspectives.
    J Thorac Oncol. 2021;16:1936-1945.
    PubMed     Abstract available


  513. SAALFELD FC, Wenzel C, Christopoulos P, Merkelbach-Bruse S, et al
    Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
    J Thorac Oncol. 2021;16:1952-1958.
    PubMed     Abstract available


  514. YEAP BY, De Rienzo A, Gill RR, Oster ME, et al
    Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:1925-1935.
    PubMed     Abstract available


    October 2021
  515. PAZ-ARES LG, Ramalingam SS, Ciuleanu TE, Lee JS, et al
    First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03207.
    PubMed     Abstract available


  516. MEZA R, Cao P, Jeon J, Taylor KL, et al
    Brief Report: Impact of joint lung cancer screening and cessation interventions under the new USPSTF recommendations.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03208.
    PubMed     Abstract available


  517. ROBBINS HA, Cheung LC, Chaturvedi AK, Baldwin DR, et al
    Management of lung cancer screening results based on individual prediction of current and future lung cancer risk.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03244.
    PubMed     Abstract available


  518. HUO KG, Notsuda H, Fang Z, Liu NF, et al
    Lung cancer driven by BRAF(G469V) mutation is targetable by EGFR kinase inhibitors.
    J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03205.
    PubMed     Abstract available


  519. SONG Z, Lian S, Mak S, Chow MZ, et al
    Deep RNA sequencing revealed fusion junctional heterogeneity may predict crizotinib treatment efficacy in ALK-rearranged non-small cell lung cancer.
    J Thorac Oncol. 2021 Oct 6. pii: S1556-0864(21)03219.
    PubMed     Abstract available


  520. DZIADZIUSZKO R, Didkowska J, Jassem J
    Authors' Reply to Role of Primary Prevention in Lung Cancer Control in Poland.
    J Thorac Oncol. 2021;16:e94-e95.
    PubMed    


  521. ZATONSKI WA, Janik-Koncewicz K, Zatonski M
    Role of Primary Prevention in Lung Cancer Control in Poland.
    J Thorac Oncol. 2021;16:e93-e94.
    PubMed    


  522. OCAK S, Tournoy K, Berghmans T, Demedts I, et al
    Lung Cancer in Belgium.
    J Thorac Oncol. 2021;16:1610-1621.
    PubMed    


  523. TSIM S, Alexander L, Kelly C, Shaw A, et al
    Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases.
    J Thorac Oncol. 2021;16:1705-1717.
    PubMed     Abstract available


  524. DERKS JL, Rijnsburger N, Hermans BCM, Moonen L, et al
    Clinical-Pathologic Challenges in the Classification of Pulmonary Neuroendocrine Neoplasms and Targets on the Horizon for Future Clinical Practice.
    J Thorac Oncol. 2021;16:1632-1646.
    PubMed     Abstract available


  525. LUO J, Beattie JA, Fuentes P, Rizvi H, et al
    Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events.
    J Thorac Oncol. 2021;16:1759-1764.
    PubMed     Abstract available


  526. DENG C, Zheng Q, Zhang Y, Jin Y, et al
    Validation of the Novel International Association for the Study of Lung Cancer Grading System for Invasive Pulmonary Adenocarcinoma and Association With Common Driver Mutations.
    J Thorac Oncol. 2021;16:1684-1693.
    PubMed     Abstract available


  527. MYRAND SP
    A Novel Oncogenic RET Fusion Variant in NSCLC: RELCH-RET.
    J Thorac Oncol. 2021;16:e95.
    PubMed    


  528. SUTEJA L, Yeong J, Tan AC, Toy W, et al
    Improving Precision and Implementation of Immuno-Oncology Biomarkers.
    J Thorac Oncol. 2021;16:e91-e93.
    PubMed    


  529. YANG H, Hall SRR, Yao F
    Improving Prediction Marker Models With the Ratio of CD39+CD8+ to Total CD8+ T cells: How Good Is Good Enough?
    J Thorac Oncol. 2021;16:e88-e91.
    PubMed    


  530. ZHAO H, Li J, Zhang Z, Zhang L, et al
    Response to "Limitations of the Hazard Ratio as a Summary Measure in Cancer Clinical Trials".
    J Thorac Oncol. 2021;16:e87-e88.
    PubMed    


  531. DAO QL, Phung Q, Liu MA
    Limitations of the Hazard Ratio as a Summary Measure in Cancer Clinical Trials.
    J Thorac Oncol. 2021;16:e86-e87.
    PubMed    


  532. FAN C, Zhao Q, Jiang Z, Xin T, et al
    Response to Letter to the Editor Titled "Intrathecal Pemetrexed: Another Potential Treatment Modality for TKI-Failed Leptomeningeal Metastases?".
    J Thorac Oncol. 2021;16:e85.
    PubMed    


  533. ZHENG MM, Li YS, Sun H, Chen HJ, et al
    Intrathecal Pemetrexed: Another Potential Treatment Modality for Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases?
    J Thorac Oncol. 2021;16:e82-e84.
    PubMed    


  534. LINDBERG K, Lax I, Karlsson K, Lewensohn R, et al
    In Response to Rosenberg et al. "The Nordic-HILUS Trial: Ultracentral Lung SABR and a Narrow Therapeutic Window".
    J Thorac Oncol. 2021;16:e81-e82.
    PubMed    


  535. ROSENBERG SA, Mak R, Kotecha R, Loo BW Jr, et al
    The Nordic-HILUS Trial: Ultracentral Lung Stereotactic Ablative Radiotherapy and a Narrow Therapeutic Window.
    J Thorac Oncol. 2021;16:e79-e80.
    PubMed    


  536. STIRLING RG
    Posttreatment Surveillance Challenges in the Era of Precision Medicine.
    J Thorac Oncol. 2021;16:e77-e78.
    PubMed    


  537. ARIK Z, Erman M
    Should Protocols Specific to Histologic Subtypes Be Applied in the Follow-Up of NSCLC?
    J Thorac Oncol. 2021;16:e77.
    PubMed    


  538. ZHANG JT, Wu YL
    Combination Chemotherapy Alone Should Be Used in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2021;16:1627-1631.
    PubMed    


  539. ZHOU F, Zhou C
    Chemotherapy Should Be Combined With Checkpoint Inhibitors in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2021;16:1622-1626.
    PubMed    


  540. MESCI A, Tsakiridis T, Swaminath A
    Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?
    J Thorac Oncol. 2021;16:1607-1609.
    PubMed    


  541. BOTTICELLA A, Levy A, Le Pechoux C
    Stage III NSCLC in Low- and Middle-Income Countries: Where Are We in 2021?
    J Thorac Oncol. 2021;16:1605-1606.
    PubMed    


  542. NICHOLSON AG, Moreira AL, Mino-Kenudson M, Popat S, et al
    Grading in Lung Adenocarcinoma: Another New Normal.
    J Thorac Oncol. 2021;16:1601-1604.
    PubMed    


  543. ROKUTAN-KURATA M, Yoshizawa A, Ueno K, Nakajima N, et al
    Validation Study of the International Association for the Study of Lung Cancer Histologic Grading System of Invasive Lung Adenocarcinoma.
    J Thorac Oncol. 2021;16:1753-1758.
    PubMed     Abstract available


    September 2021
  544. SALEH MM, Scheffler M, Merkelbach-Bruse S, Scheel AH, et al
    Comprehensive Analysis of TP53 and KEAP1 Mutations and their Impact on Survival in Localized and Advanced Stage Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Sep 30. pii: S1556-0864(21)03187.
    PubMed     Abstract available


  545. QU S, Fetsch P, Thomas A, Pommier Y, et al
    Molecular Subtypes of Primary Small Cell Lung Cancer Tumors and Their Associations with Neuroendocrine and Therapeutic Markers.
    J Thorac Oncol. 2021 Sep 14. pii: S1556-0864(21)03186.
    PubMed     Abstract available


  546. NISHINO M, Hatabu H, Ricciuti B, Vaz V, et al
    Brief Report Axillary lymphadenopathy after COVID-19 vaccinations in patients with thoracic malignancy: Incidence, predisposing factors, and imaging characteristics.
    J Thorac Oncol. 2021 Sep 7. pii: S1556-0864(21)03184.
    PubMed     Abstract available


  547. BESTVINA CM, Pointer KB, Karrison T, Al-Hallaq H, et al
    A Phase I Trial of Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study).
    J Thorac Oncol. 2021 Sep 6. pii: S1556-0864(21)02441.
    PubMed     Abstract available


  548. TRAN HTT, Nguyen S, Nguyen KK, Pham DX, et al
    Lung Cancer in Vietnam.
    J Thorac Oncol. 2021;16:1443-1448.
    PubMed    


  549. SINGH AK, Sands JM
    Yet Another Reminder of the Value of Lung Cancer Screening.
    J Thorac Oncol. 2021;16:1437-1439.
    PubMed    


  550. ZHAO H, Zhang Z, Zhang L
    Response to: The Role of Dual Inhibition of EGFR and Vascular EGF(R) in the Treatment of NSCLC With EGFR Mutation.
    J Thorac Oncol. 2021;16:e72-e76.
    PubMed    


  551. YAMAOKA T, Kim YH, Iwatsubo S, Nishimura Y, et al
    The Role of Dual Inhibition of EGFR and Vascular Endothelial Growth Factor (Receptor) in the Treatment of NSCLC With EGFR Mutation.
    J Thorac Oncol. 2021;16:e71-e72.
    PubMed    


  552. BORZI C, Caiola E, Ganzinelli M, Centonze G, et al
    miR-17 Epigenetic Modulation of LKB1 Expression in Tumor Cells Uncovers a New Group of Patients With Poor-Prognosis NSCLC.
    J Thorac Oncol. 2021;16:e68-e70.
    PubMed    


  553. BI G, Liang J, Shan G, Zhan C, et al
    Some Thoughts Concerning the Mutational Background of Cell Lines and Heterogeneity of Bulk Tumor.
    J Thorac Oncol. 2021;16:e67-e68.
    PubMed    


  554. LEE HY
    A Wake-Up Call for Immune Checkpoint Inhibitor-Related Pneumonitis.
    J Thorac Oncol. 2021;16:1440-1442.
    PubMed    


  555. BIRONZO P, Passiglia F, Novello S
    Winds From the ORIENT: New Data to Inform RATIONAL Choice?
    J Thorac Oncol. 2021;16:1434-1436.
    PubMed    


  556. UPRETY D, Remon J, Adjei AA
    All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC.
    J Thorac Oncol. 2021;16:1429-1433.
    PubMed    


  557. LIAO BC, Chih-Hsin Yang J
    Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:1426-1428.
    PubMed    


  558. NAKASHIMA K, Tsubata Y, Niihara H, Araki A, et al
    Palm Pustules Induced by Pemetrexed.
    J Thorac Oncol. 2021;16:1589-1591.
    PubMed    


  559. POZZESSERE C, Lazor R, Jumeau R, Peters S, et al
    Imaging Features of Pulmonary Immune-related Adverse Events.
    J Thorac Oncol. 2021;16:1449-1460.
    PubMed     Abstract available


  560. VANDENHOECK J, van Meerbeeck JP, Fransen E, Raskin J, et al
    DNA Methylation as a Diagnostic Biomarker for Malignant Mesothelioma: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2021;16:1461-1478.
    PubMed     Abstract available


    August 2021
  561. CAMIDGE DR, Kim HR, Ahn MJ, Yang JC, et al
    Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial.
    J Thorac Oncol. 2021 Aug 30. pii: S1556-0864(21)02398.
    PubMed     Abstract available


  562. DOROSHOW DB, Wei W, Gupta S, Zugazagoitia J, et al
    PD-L1 tumor proportion score and overall survival from first-line pembrolizumab in patients with nonsquamous versus squamous non-small cell lung cancer.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02392.
    PubMed     Abstract available


  563. PLANCHARD D, Besse B, Groen HJM, Hashemi SMS, et al
    Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: Updated 5-year survival rates and genomic analysis.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02403.
    PubMed     Abstract available


  564. THOMAS NJ, Myall NJ, Sun F, Patil T, et al
    Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02401.
    PubMed     Abstract available


  565. KERPEL-FRONIUS A, Tammemagi M, Cavic M, Henschke C, et al
    Screening for lung cancer in individuals who never smoked: An IASLC Early Detection and Screening Committee Report.
    J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02391.
    PubMed     Abstract available


  566. SHIRASAWA M, Yoshida T, Shimoda Y, Takayanagi D, et al
    Differential Immune-Related Microenvironment Determines PD-1/PD-L1 Blockade Efficacy in Advanced Non-Small Cell Lung Cancer Patients.
    J Thorac Oncol. 2021 Aug 19. pii: S1556-0864(21)02373.
    PubMed     Abstract available


  567. YAMAGUCHI H, Wakuda K, Fukuda M, Kenmotsu H, et al
    A phase II study of osimertinib for radiotherapy-naive CNS metastasis from non-small cell lung cancer: Results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116L).
    J Thorac Oncol. 2021 Aug 19. pii: S1556-0864(21)02372.
    PubMed     Abstract available


  568. WALIANY S, Zhu H, Wakelee H, Padda SK, et al
    Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.
    J Thorac Oncol. 2021 Aug 18. pii: S1556-0864(21)02377.
    PubMed     Abstract available


  569. QUAIFE SL, Dickson JL, Brain KE, Kurtidu C, et al
    Psychological targets for lung cancer screening uptake: a prospective longitudinal cohort study.
    J Thorac Oncol. 2021 Aug 14. pii: S1556-0864(21)02369.
    PubMed     Abstract available


  570. HERZOG BH, Devarakonda S, Govindan R
    Overcoming chemotherapy resistance in Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Aug 3. pii: S1556-0864(21)02333.
    PubMed    


  571. AREDO JV, Wakelee HA, Han SS
    A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer.
    J Thorac Oncol. 2021;16:e59-e60.
    PubMed    


  572. PELOSI G, Pasini F
    Over-Time Risk of Lung Cancer Is Largely Owing to Continuing Smoking Exposition: A Good Reason to Quit.
    J Thorac Oncol. 2021;16:e57-e59.
    PubMed    


  573. SINGH N, Agrawal S, Jiwnani S, Khosla D, et al
    Lung Cancer in India.
    J Thorac Oncol. 2021;16:1250-1266.
    PubMed    


  574. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Reaction on the Interpretation of the Hippocampus Avoidance Prophylactic Cranial Irradiation Trial in SCLC (NCT01780675).
    J Thorac Oncol. 2021;16:e63-e65.
    PubMed    


  575. MLADKOVA N, Lo S, Brown PD, Gondi V, et al
    Hippocampal Avoidance Prophylactic Cranial Irradiation: Interpreting the Evidence.
    J Thorac Oncol. 2021;16:e60-e63.
    PubMed    


  576. COOPER WA, Lantuejoul S, Mino-Kenudson M
    Predicting Response to Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Blockade in NSCLC-Is Multiplex Immunohistochemistry or Immunofluorescence the Answer?
    J Thorac Oncol. 2021;16:1247-1249.
    PubMed    


  577. RUIZ J, Chan M, Strowd RE
    Treatment of Leptomeningeal Metastases: New Hammer, the Same Nail.
    J Thorac Oncol. 2021;16:1244-1246.
    PubMed    


  578. SMIT EF, Belderbos J
    Concurrent Chemoradiation, Adjuvant Durvalumab, and KEAP-1/NRF-2 Mutations: A Happy Marriage?
    J Thorac Oncol. 2021;16:1242-1243.
    PubMed    


  579. COLOMBO M, Ndembe G, Broggini M
    KRAS Targeting and Resistance: Anticipating the Expectable.
    J Thorac Oncol. 2021;16:1239-1241.
    PubMed    


  580. HUDDAR P, Califano R
    Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibition as Maintenance Treatment for SCLC: The Search Must Continue.
    J Thorac Oncol. 2021;16:1236-1238.
    PubMed    


  581. SHAVERDIAN N, Offin M, Shepherd AF, Simone CB 2nd, et al
    The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors.
    J Thorac Oncol. 2021;16:1392-1402.
    PubMed     Abstract available


  582. FAN C, Zhao Q, Li L, Shen W, et al
    Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier:
    J Thorac Oncol. 2021;16:1359-1368.
    PubMed     Abstract available


  583. YEONG J, Suteja L, Simoni Y, Lau KW, et al
    Intratumoral CD39(+)CD8(+) T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC.
    J Thorac Oncol. 2021;16:1349-1358.
    PubMed     Abstract available


  584. KOGA T, Suda K, Fujino T, Ohara S, et al
    KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    J Thorac Oncol. 2021;16:1321-1332.
    PubMed     Abstract available


  585. YOTSUKURA M, Asamura H, Motoi N, Kashima J, et al
    Long-Term Prognosis of Patients With Resected Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung.
    J Thorac Oncol. 2021;16:1312-1320.
    PubMed     Abstract available


  586. BORZI C, Ganzinelli M, Caiola E, Colombo M, et al
    LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments.
    J Thorac Oncol. 2021;16:1298-1311.
    PubMed     Abstract available


    July 2021
  587. DZIADZIUSZKO R, Mok T, Peters S, Han JY, et al
    Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02321.
    PubMed     Abstract available


  588. PATEL SA, Herynk MH, Cascone T, Saigal B, et al
    Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02320.
    PubMed     Abstract available


  589. SOCINSKI MA, Nishio M, Jotte RM, Cappuzzo F, et al
    IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02322.
    PubMed     Abstract available


  590. SMELTZER MP, Lee YS, Faris NR, Fehnel C, et al
    Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected Non-small Cell Lung Cancer (NSCLC) in a High Mortality Area of the United States.
    J Thorac Oncol. 2021 Jul 16. pii: S1556-0864(21)02299.
    PubMed     Abstract available


  591. STEWART CA, Gay CM, Ramkumar K, Cargill KR, et al
    Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.
    J Thorac Oncol. 2021 Jul 15. pii: S1556-0864(21)02294.
    PubMed     Abstract available


  592. JASSEM J, de Marinis F, Giaccone G, Vergnenegre A, et al
    Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02286.
    PubMed     Abstract available


  593. AI X, Wang Q, Cheng Y, Liu X, et al
    Safety but Limited Efficacy of Ensartinib in ROS1-Positive Non-small Cell Lung Cancer: A Single-arm, Multicenter Phase II study.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02290.
    PubMed     Abstract available


  594. POWELL SF, Rodriguez-Abreu D, Langer CJ, Tafreshi A, et al
    Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02287.
    PubMed     Abstract available


  595. MYERS R, Brauer M, Dummer T, Atkar-Khattra S, et al
    High Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers with Lung Cancer.
    J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02256.
    PubMed     Abstract available


  596. WANG Y, Li J, Chang S, Dong Y, et al
    Risk and influencing factors for subsequent primary lung cancer after treatment of breast cancer: a systematic review and two meta-analyses based on four million cases.
    J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02293.
    PubMed     Abstract available


  597. ROLFO C, Mack P, Scagliotti GV, Aggarwal C, et al
    Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC).
    J Thorac Oncol. 2021 Jul 8. pii: S1556-0864(21)02284.
    PubMed    


  598. HANN CL, Burns TF, Dowlati A, Morgensztern D, et al
    Brief Report: A Phase 1 Study Evaluating Rovalpituzumab Tesirine (Rova-T) in Frontline Treatment of Patients With Extensive-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02289.
    PubMed     Abstract available


  599. PARK HR, Kim TM, Lee Y, Kim S, et al
    Acquired resistance to third-generation EGFR tyrosine kinase inhibitors in patients with de novo EGFR(T790M)-mutant non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02254.
    PubMed     Abstract available


  600. KUMAR A, Kumar S, Gilja S, Potter A, et al
    Reconsidering the American Joint Committee on Cancer 8(th) Edition TNM Staging Manual Classifications for T2b/T3 Non-small-cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02283.
    PubMed     Abstract available


  601. MOUNTZIOS G, Gkiozos I, Stratakos G, Pissakas G, et al
    Lung Cancer in Greece.
    J Thorac Oncol. 2021;16:1058-1066.
    PubMed    


  602. UGUEN A
    Each RET Break-Apart Fluorescence In Situ Hybridization Probe Requires Proper Interpretation Criteria.
    J Thorac Oncol. 2021;16:e55.
    PubMed    


  603. ZHU VW, Zhang SS, Zhang J, Swensen J, et al
    Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib.
    J Thorac Oncol. 2021;16:e51-e54.
    PubMed    


  604. DOWLATI A, Chan T
    Pursuing Immunotherapeutic Targets in SCLC.
    J Thorac Oncol. 2021;16:1056-1057.
    PubMed    


  605. GRANNIS FW JR
    Do Cancer Screening Researchers Have a Continuing Ethical Obligation to Their Study Subjects?
    J Thorac Oncol. 2021;16:1053-1055.
    PubMed    



  606. Dr. Gouri Shankar Bhattacharyya, MD, PhD, FRCP: In Memoriam (October 31, 1958-May 1, 2021).
    J Thorac Oncol. 2021;16:1043-1044.
    PubMed    


  607. LE-RADEMACHER J, Wang X
    Time-To-Event Data: An Overview and Analysis Considerations.
    J Thorac Oncol. 2021;16:1067-1074.
    PubMed     Abstract available


  608. GOODWIN D, Rathi V, Conron M, Wright GM, et al
    Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing.
    J Thorac Oncol. 2021;16:1166-1175.
    PubMed     Abstract available


  609. YANG SR, Chang JC, Leduc C, Tan KS, et al
    Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling.
    J Thorac Oncol. 2021;16:1188-1199.
    PubMed     Abstract available


  610. LINDBERG K, Grozman V, Karlsson K, Lindberg S, et al
    The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy.
    J Thorac Oncol. 2021;16:1200-1210.
    PubMed     Abstract available


  611. HAN DH, Duan F, Wu Y, Goo JM, et al
    Clinical Significance of Lung-RADS Category 3 Lesions in the National Lung Screening Trial.
    J Thorac Oncol. 2021;16:1118-1126.
    PubMed     Abstract available


    June 2021
  612. WARREN GW, Lim VS, Chowdhary M, Marwaha G, et al
    Brief Report: New Pulmonary Infiltrates Observed on Computed Tomography Based Image Guidance for Radiotherapy Warrant Diagnostic Workup for COVID-19.
    J Thorac Oncol. 2021 Jun 21. pii: S1556-0864(21)02232.
    PubMed     Abstract available


  613. AKAMATSU H, Murakami H, Harada H, Shimizu J, et al
    Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L.
    J Thorac Oncol. 2021 Jun 8. pii: S1556-0864(21)02190.
    PubMed     Abstract available


  614. SU CC, Wu JT, Neal JW, Popat RA, et al
    Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.
    J Thorac Oncol. 2021 Jun 3. pii: S1556-0864(21)02181.
    PubMed     Abstract available


  615. ANG YLE, Chia PL, Chua KLM, Devanand A, et al
    Lung Cancer in Singapore.
    J Thorac Oncol. 2021;16:906-911.
    PubMed    


  616. RAMI-PORTA R, Goldstraw P, Asamura H
    Commemorating the Silver Anniversary of the International Association for the Study of Lung Cancer International Workshop on Intrathoracic Staging.
    J Thorac Oncol. 2021;16:902-905.
    PubMed    


  617. GRASS GD, Scott JG, Sedor G, Kattan MW, et al
    Response to: Noncancer Cells in Tumor Samples May Bias the Predictive Genomically Adjusted Radiation Dose.
    J Thorac Oncol. 2021;16:e48-e49.
    PubMed    


  618. DU Y, Hu Z, Liang J, Zhan C, et al
    Noncancer Cells in Tumor Samples May Bias the Predictive Genomic-Adjusted Radiation Dose.
    J Thorac Oncol. 2021;16:e47.
    PubMed    


  619. RYAN BM
    In Response: Using Propensity Score Matching to Balance the Baseline Characteristics.
    J Thorac Oncol. 2021;16:e46.
    PubMed    


  620. LIANG J, Hu Z, Zhan C, Wang Q, et al
    Using Propensity Score Matching to Balance the Baseline Characteristics.
    J Thorac Oncol. 2021;16:e45-e46.
    PubMed    


  621. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Why Did the Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC Not Reveal a Difference?
    J Thorac Oncol. 2021;16:e42-e45.
    PubMed    


  622. BREEN WG, Brown PD, Laack NN
    Hippocampal Avoidance Prophylactic Cranial Irradiation for SCLC.
    J Thorac Oncol. 2021;16:e41-e42.
    PubMed    


  623. DEUTSCH E, Cengel KA, Galluzzi L, Levy A, et al
    Could Protons Promote Tumor Control by Avoiding Lymphopenia?
    J Thorac Oncol. 2021;16:e39-e41.
    PubMed    


  624. BAUMAN J, Borghaei H
    To Give or Not to Give: Consolidative Durvalumab in EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:894-896.
    PubMed    


  625. WARREN GW, Evans WK, Dresler C
    Critical Determinants of Cancer Treatment Outcomes: Smoking Must Be Addressed at the Highest Levels in Cancer Care.
    J Thorac Oncol. 2021;16:891-893.
    PubMed    


  626. CAMIDGE DR, Otterson GA, Clark JW, Ignatius Ou SH, et al
    Crizotinib in Patients With MET-Amplified NSCLC.
    J Thorac Oncol. 2021;16:1017-1029.
    PubMed     Abstract available


  627. FINN SP, Addeo A, Dafni U, Thunnissen E, et al
    Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
    J Thorac Oncol. 2021;16:990-1002.
    PubMed     Abstract available


  628. STEUER CE, Jegede OA, Dahlberg SE, Wakelee HA, et al
    Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial.
    J Thorac Oncol. 2021;16:960-967.
    PubMed     Abstract available


    May 2021
  629. JAZIEH AR, Onal HC, Weng Tan DS, Soo RA, et al
    Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: Results of KINDLE, a multi-country observational study.
    J Thorac Oncol. 2021 May 26. pii: S1556-0864(21)02174.
    PubMed     Abstract available


  630. ZHOU C, Wu L, Fan Y, Wang Z, et al
    Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12).
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02128.
    PubMed     Abstract available


  631. HERBST RS, Garon EB, Kim DW, Cho BC, et al
    5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02172.
    PubMed     Abstract available


  632. JOHNSON AM, Boland JM, Wrobel J, Klezcko EK, et al
    Cancer cell-specific MHCII expression as a determinant of the immune infiltrate organization and function in the non-small cell lung cancer tumor microenvironment.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02175.
    PubMed     Abstract available


  633. BARBI J, Patnaik SK, Pabla S, Zollo R, et al
    Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02171.
    PubMed     Abstract available


  634. LU S, Wang J, Yu Y, Yu X, et al
    Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial.
    J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02176.
    PubMed     Abstract available


  635. ZHAO H, Yao W, Min X, Gu K, et al
    Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706).
    J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02177.
    PubMed     Abstract available


  636. LOIOLA DE ALENCAR VT, Camandaroba MPG, Pirolli R, Fogassa CAZ, et al
    Immunotherapy as Single Treatment for Non-small-cell Lung Cancer Patients with Brain Metastases: a systematic review and meta-analysis - the META-L-BRAIN study.
    J Thorac Oncol. 2021 May 5. pii: S1556-0864(21)02131.
    PubMed     Abstract available


  637. OSAROGIAGBON RU, Ray MA, Faris NR, Smeltzer MP, et al
    Response to: "Lymph Node Dissection for Non-Small-Cell Lung Cancer at Whose Discretion?"
    J Thorac Oncol. 2021;16:e36-e37.
    PubMed    


  638. PIRKER R, Prosch H, Popper H, Klepetko W, et al
    Lung Cancer in Austria.
    J Thorac Oncol. 2021;16:725-733.
    PubMed    


  639. KIM CG, Cho BC, Lim SM
    Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?
    J Thorac Oncol. 2021;16:709-711.
    PubMed    


  640. LI M, Zhan C, Wang Q
    Is the Story of M Descriptors Fulfilled or Finished?
    J Thorac Oncol. 2021;16:e36-e37.
    PubMed    


  641. METOVIC J, Bianchi F, Barella M, Papotti M, et al
    SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas.
    J Thorac Oncol. 2021;16:e32-e35.
    PubMed    


  642. DE CARLO E, Schiappacassi M, Del Conte A, Stanzione B, et al
    Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC.
    J Thorac Oncol. 2021;16:e31-e32.
    PubMed    


  643. NISHIO M, Mendus D, Wang L, Socinski MA, et al
    Response to Letter to the Editor.
    J Thorac Oncol. 2021;16:e30-e31.
    PubMed    


  644. DI FEDERICO A, Nuvola G, Deiana C, Donati G, et al
    IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
    J Thorac Oncol. 2021;16:e29-e30.
    PubMed    


  645. SEDOR G, Scott JG, Kattan MW, Torres-Roca JF, et al
    Letter Response.
    J Thorac Oncol. 2021;16:e28-e29.
    PubMed    


  646. MISTRY HB
    Simulating RTOG 0617 using Genomic Adjusted Radiation Dose: Comparing Apples With Oranges.
    J Thorac Oncol. 2021;16:e27.
    PubMed    


  647. RIMNER A, Wu AJ, Grills IS
    What Is the Impact of Hippocampus Avoidance-Prophylactic Cranial Irradiation on Neurocognitive Preservation?
    J Thorac Oncol. 2021;16:722-724.
    PubMed    


  648. WESTEEL V
    Surveillance After Curative-Intent Treatment for NSCLC: More to It Than Meets the Eye.
    J Thorac Oncol. 2021;16:719-721.
    PubMed    


  649. JULOORI A, Vokes EE
    Beyond PACIFIC: Uncharted Waters.
    J Thorac Oncol. 2021;16:715-718.
    PubMed    


  650. LIU SY, Wu YL
    Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic Alterations.
    J Thorac Oncol. 2021;16:712-714.
    PubMed    


  651. ADJEI AA, Ignatius Ou SH, Ho C, Pujol JL, et al
    Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships.
    J Thorac Oncol. 2021;16:706-708.
    PubMed    


  652. MATSUI S, Le-Rademacher J, Mandrekar SJ
    Statistical Models in Clinical Studies.
    J Thorac Oncol. 2021;16:734-739.
    PubMed     Abstract available


  653. STIRLING RG, Chau C, Shareh A, Zalcberg J, et al
    Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2021;16:784-797.
    PubMed     Abstract available


  654. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).
    J Thorac Oncol. 2021;16:840-849.
    PubMed     Abstract available


  655. HELLYER JA, Aredo JV, Das M, Ramchandran K, et al
    Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
    J Thorac Oncol. 2021;16:868-872.
    PubMed     Abstract available


  656. FAIVRE-FINN C, Vicente D, Kurata T, Planchard D, et al
    Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
    J Thorac Oncol. 2021;16:860-867.
    PubMed     Abstract available


  657. NAGASAKA M, Zhu VW, Lim SM, Greco M, et al
    Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
    J Thorac Oncol. 2021;16:740-763.
    PubMed     Abstract available


  658. PASSARO A, Mok T, Peters S, Popat S, et al
    Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.
    J Thorac Oncol. 2021;16:764-773.
    PubMed     Abstract available


    April 2021
  659. AI X, Pan Y, Shi J, Yang N, et al
    Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02111.
    PubMed     Abstract available


  660. YONESHIMA Y, Morita S, Ando M, Nakamura A, et al
    Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02107.
    PubMed     Abstract available


  661. HWANG DM, Albaqer T, Santiago RC, Weiss J, et al
    Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02108.
    PubMed     Abstract available


  662. QIAO M, Jiang T, Liu X, Mao S, et al
    Immune checkpoint inhibitors in EGFR-mutated non-small cell lung cancer: Dusk or Dawn?
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02113.
    PubMed     Abstract available


  663. ANDRUSKA N, Stowe HB, Crockett C, Liu W, et al
    Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios.
    J Thorac Oncol. 2021 Apr 23. pii: S1556-0864(21)02112.
    PubMed     Abstract available


  664. SAFIRI S, Sohrabi MR, Carson-Chahhoud K, Bettampadi D, et al
    Burden of tracheal, bronchus and lung cancer and its attributable risk factors in 204 countries and territories, 1990-2019.
    J Thorac Oncol. 2021 Apr 15. pii: S1556-0864(21)02110.
    PubMed     Abstract available


  665. PATAER A, Weissferdt A, Vaporciyan AA, Correa AM, et al
    Evaluation of Pathologic Response in Lymph Nodes of Lung Cancer Patients Receiving Neoadjuvant Chemotherapy.
    J Thorac Oncol. 2021 Apr 12. pii: S1556-0864(21)02109.
    PubMed     Abstract available


  666. BAUMEISTER SE, Baurecht H, Nolde M, Alayash Z, et al
    Cannabis use, pulmonary function, and lung cancer susceptibility: A Mendelian randomization study.
    J Thorac Oncol. 2021 Apr 11. pii: S1556-0864(21)02105.
    PubMed     Abstract available


  667. MEMMOTT RM, Wolfe AR, Carbone DP, Williams TM, et al
    Predictors of Response, Progression Free Survival, and Overall Survival in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)02072.
    PubMed     Abstract available


  668. PARK K, Ozguroglu M, Vansteenkiste J, Spigel D, et al
    Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)01832.
    PubMed     Abstract available


  669. ALESSI JV, Ricciuti B, Spurr LF, Gupta H, et al
    SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: Clinicopathological characteristics and outcomes to immune checkpoint inhibition.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)02104.
    PubMed     Abstract available


  670. LIU L, Bai H, Wang C, Seery S, et al
    Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02071.
    PubMed     Abstract available


  671. ODINTSOV I, Mattar MS, Lui AJW, Offin M, et al
    Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02068.
    PubMed     Abstract available


  672. THOMAS PL, Groves SM, Zhang YK, Li J, et al
    Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02066.
    PubMed     Abstract available


  673. JOHNSON ML, Zvirbule Z, Laktionov K, Helland A, et al
    Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.
    J Thorac Oncol. 2021 Apr 3. pii: S1556-0864(21)02067.
    PubMed     Abstract available


  674. GOTO T
    Lymph Node Dissection for NSCLC at Whose Discretion?
    J Thorac Oncol. 2021;16:e25.
    PubMed    


  675. PAZ-ARES L
    Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLC.
    J Thorac Oncol. 2021;16:e24.
    PubMed    


  676. XU J, Nie H, Wan H
    Bintrafusp Alfa in the Second-Line Treatment of Patients With NSCLC.
    J Thorac Oncol. 2021;16:e23-e24.
    PubMed    


  677. QIU H, Li Q, Xiao Y, Wu D, et al
    A Novel Intergenic Region Between KLHL31 and LRRC1-ALK Exon 20 Fusion Variant in Advanced Lung Adenocarcinoma and its Remarkable Response to ALK Inhibitor.
    J Thorac Oncol. 2021;16:e21-e23.
    PubMed    


  678. NAGASAKA M, Ou SI
    Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.
    J Thorac Oncol. 2021;16:532-536.
    PubMed    


  679. CAMIDGE DR
    Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
    J Thorac Oncol. 2021;16:528-531.
    PubMed    


  680. GADGEEL SM
    Patient-Reported Outcomes in the Era of Immunotherapy Trials.
    J Thorac Oncol. 2021;16:516-518.
    PubMed    


  681. FALKSON CB
    Postoperative Radiation for Completely Resected Stage II/III Thymoma: What Do We Know in 2021?
    J Thorac Oncol. 2021;16:515.
    PubMed    


  682. PATEL SP, Kelly K
    IMpower 132: Loses Power at the Finish Line.
    J Thorac Oncol. 2021;16:512-514.
    PubMed    


  683. PACHECO JM, Schenk EL
    CD73 and Adenosine Receptor Signaling as a Potential Therapeutic Target in EGFR-Mutated NSCLC.
    J Thorac Oncol. 2021;16:509-511.
    PubMed    


  684. SEBASTIAN M, Stratmann JA, Eberhardt WEE
    Too Good to be True?
    J Thorac Oncol. 2021;16:507-508.
    PubMed    


  685. LE X
    Heterogeneity in MET-Aberrant NSCLC.
    J Thorac Oncol. 2021;16:504-506.
    PubMed    


  686. OU FS, Michiels S, Shyr Y, Adjei AA, et al
    Biomarker Discovery and Validation: Statistical Considerations.
    J Thorac Oncol. 2021;16:537-545.
    PubMed     Abstract available


  687. TATEISHI Y, Horita N, Namkoong H, Enomoto T, et al
    Postoperative Radiotherapy for Completely Resected Masaoka/Masaoka-Koga Stage II/III Thymoma Improves Overall Survival: An Updated Meta-Analysis of 4746 Patients.
    J Thorac Oncol. 2021;16:677-685.
    PubMed     Abstract available


  688. LE X, Negrao MV, Reuben A, Federico L, et al
    Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
    J Thorac Oncol. 2021;16:583-600.
    PubMed     Abstract available


  689. LAM VK, Zhang J, Wu CC, Tran HT, et al
    Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
    J Thorac Oncol. 2021;16:601-609.
    PubMed     Abstract available


  690. VILLALBA JA, Shih AR, Sayo TMS, Kunitoki K, et al
    Accuracy and Reproducibility of Intraoperative Assessment on Tumor Spread Through Air Spaces in Stage 1 Lung Adenocarcinomas.
    J Thorac Oncol. 2021;16:619-629.
    PubMed     Abstract available


  691. MOONEN L, Derks JL, Hermans BCM, Bunnik IM, et al
    Preoperative Biopsy Diagnosis in Pulmonary Carcinoids, a Shot in the Dark.
    J Thorac Oncol. 2021;16:610-618.
    PubMed     Abstract available


    March 2021
  692. SCARFONE G, Fumagalli M, Imbimbo M, Ceruti T, et al
    First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
    J Thorac Oncol. 2021 Mar 29. pii: S1556-0864(21)01705.
    PubMed     Abstract available


  693. DY GK, Prasad D, Kumar P, Attwood K, et al
    A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy.
    J Thorac Oncol. 2021;16:e19-e20.
    PubMed    


  694. YANG X, Li Y, Duan Q, Zhang Q, et al
    Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment.
    J Thorac Oncol. 2021;16:e17-e19.
    PubMed    


  695. SHIELDS MD, Hicks JK, Boyle TA, Haura EB, et al
    Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib.
    J Thorac Oncol. 2021;16:e15-e17.
    PubMed    


  696. UPRETY D
    Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.
    J Thorac Oncol. 2021;16:371-374.
    PubMed    


  697. REMON J, Hendriks LEL
    Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:368-370.
    PubMed    


  698. ADJEI AA
    Controversies in Thoracic Oncology.
    J Thorac Oncol. 2021;16:366-367.
    PubMed    


  699. RAJAN A
    Immunotherapy for Thymic Cancers: A Convoluted Path Toward a Cherished Goal.
    J Thorac Oncol. 2021;16:352-354.
    PubMed    


  700. SONG L, Xu Q, Lizaso A, Zhang Y, et al
    Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC.
    J Thorac Oncol. 2021;16:349-351.
    PubMed    


  701. SONG Z, Lu C, Xu CW, Zheng Z, et al
    Noncanonical Gene Fusions Detected at the DNA Level Necessitate Orthogonal Diagnosis Methods Before Targeted Therapy.
    J Thorac Oncol. 2021;16:344-348.
    PubMed    


  702. WANG X, Piantadosi S, Le-Rademacher J, Mandrekar SJ, et al
    Statistical Considerations for Subgroup Analyses.
    J Thorac Oncol. 2021;16:375-380.
    PubMed    


  703. NILSSON MB, Robichaux J, Herynk MH, Cascone T, et al
    Altered Regulation of HIF-1alpha in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.
    J Thorac Oncol. 2021;16:439-451.
    PubMed     Abstract available


  704. NG TL, Johnson A, Nemenoff RA, Hsieh E, et al
    Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation.
    J Thorac Oncol. 2021;16:486-491.
    PubMed     Abstract available


  705. LI W, Guo L, Liu Y, Dong L, et al
    Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
    J Thorac Oncol. 2021;16:404-418.
    PubMed     Abstract available


  706. GIACCONE G, Kim C
    Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up.
    J Thorac Oncol. 2021;16:483-485.
    PubMed     Abstract available


  707. SECHI E, Zekeridou A
    Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies.
    J Thorac Oncol. 2021;16:381-394.
    PubMed     Abstract available


    February 2021
  708. LEE J, Ahn MJ
    A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
    J Thorac Oncol. 2021;16:e14.
    PubMed    


  709. ZHENG MM, Li YS, Sun H, Wu YL, et al
    Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
    J Thorac Oncol. 2021;16:e12-e14.
    PubMed    


  710. TSUI DCC, Camidge DR
    Molecular Profiling of the Cerebrospinal Fluid in Leptomeningeal NSCLC: The Shape of Things to Come?
    J Thorac Oncol. 2021;16:194-196.
    PubMed    


  711. SEQUIST LV, Skates SJ, Haas W
    A New Era of Protein-Based Assays for Cancer Early Detection.
    J Thorac Oncol. 2021;16:191-193.
    PubMed    


  712. FERRARA R, Campochiaro C, Garassino MC
    Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events.
    J Thorac Oncol. 2021;16:183-186.
    PubMed    


  713. PADDA SK, Reckamp KL
    Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-a Rational Approach.
    J Thorac Oncol. 2021;16:178-182.
    PubMed    


  714. MOK T, Peters S, Camidge DR, Noe J, et al
    Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
    J Thorac Oncol. 2021;16:259-268.
    PubMed     Abstract available


  715. LI B, Zhang Y, Miao L, Ma L, et al
    Esophagectomy With Three-Field Versus Two-Field Lymphadenectomy for Middle and Lower Thoracic Esophageal Cancer: Long-Term Outcomes of a Randomized Clinical Trial.
    J Thorac Oncol. 2021;16:310-317.
    PubMed     Abstract available


  716. BANFILL K, Giuliani M, Aznar M, Franks K, et al
    Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions.
    J Thorac Oncol. 2021;16:216-227.
    PubMed     Abstract available


  717. GJYSHI O, Xu T, Elhammali A, Boyce-Fappiano D, et al
    Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.
    J Thorac Oncol. 2021;16:269-277.
    PubMed     Abstract available


  718. PETERS S, Felip E, Dafni U, Tufman A, et al
    Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology P
    J Thorac Oncol. 2021;16:278-288.
    PubMed     Abstract available


  719. JIANG T, Fang Z, Tang S, Cheng R, et al
    Mutational Landscape and Evolutionary Pattern of Liver and Brain Metastasis in Lung Adenocarcinoma.
    J Thorac Oncol. 2021;16:237-249.
    PubMed     Abstract available


  720. OSTRIN EJ, Bantis LE, Wilson DO, Patel N, et al
    Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules.
    J Thorac Oncol. 2021;16:228-236.
    PubMed     Abstract available


  721. LE X, Nilsson M, Goldman J, Reck M, et al
    Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:205-215.
    PubMed     Abstract available


  722. MOI L, Bouchaab H, Mederos N, Nguyen-Ngoc T, et al
    Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
    J Thorac Oncol. 2021;16:318-326.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.